10-Q

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

0001193125-19-146603.txt : 20190514 0001193125-19-146603.hdr.sgml : 20190514 20190514163654 ACCESSION NUMBER: 0001193125-19-146603 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20190331 FILED AS OF DATE: 20190514 DATE AS OF CHANGE: 20190514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LogicBio Therapeutics, Inc. CENTRAL INDEX KEY: 0001664106 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 471514975 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38707 FILM NUMBER: 19823304 BUSINESS ADDRESS: STREET 1: 99 ERIE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-245-0399 MAIL ADDRESS: STREET 1: 99 ERIE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 10-Q 1 d730342d10q.htm 10-Q 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2019

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-38707

LogicBio Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware

47-1514975

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

99 Erie St., Cambridge, MA 02139

(Address of principal executive offices) (Zip code)

(617) 245-0399

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	LOGC	Nasdaq Global Market

As of May 10, 2019, the registrant had 22,494,299 shares of common stock, $0.0001 par value per share, outstanding.

Table of Contents


		Page
PART I.	FINANCIAL INFORMATION
Item 1.	Financial Statements		4
	Condensed Consolidated Balance Sheets as of March 31, 2019 and December 31, 2018 (Unaudited)		4
	Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2019 and 2018 (Unaudited)		5
	Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2019 and 2018 (Unaudited)		6
	Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the Three Months Ended March 31, 2019 and 2018 (Unaudited)		7
	Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2019 and 2018 (Unaudited)		8
	Notes to Condensed Consolidated Financial Statements (Unaudited)		9
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		16
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		22
Item 4.	Controls and Procedures		22

PART II.	OTHER INFORMATION
Item 1.	Legal Proceedings		24
Item 1A.	Risk Factors		24
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds From Sales of Registered Securities		24
Item 6.	Exhibits		25
Signatures			26

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements. In some cases, you can identify these statements by forward-looking words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “expect,” or similar expressions, or the negative or plural of these words or expressions. These forward-looking statements include statements concerning the following:

•

the initiation, cost, timing, progress and results of our current and future research and development activities and preclinical studies and potential future clinical trials;

•

potential attributes and benefits of our GeneRide technology platform and our product candidate and any future product candidates;

•

our ability to take advantage of the modular nature of our GeneRide platform to simplify and accelerate development of new product candidates;

•

the potential benefits of strategic partnership agreements and our ability to enter into selective strategic partnership arrangements;

•

the timing of, and our ability to obtain and maintain, regulatory approvals for our product candidate and any future product candidates;

•

our ability to quickly and efficiently identify and develop additional product candidates;

•

our ability to advance any product candidate into and successfully complete clinical trials;

•

our intellectual property position, including with respect to our trade secrets and the duration of our patent protection; and

•

our estimates regarding expenses, future revenues, capital requirements, the sufficiency of our current and expected cash resources and our need for additional financing.

These statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in greater detail under Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission on April 1, 2019, as may be amended or updated in our Quarterly Reports on Form 10-Q. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we are under no duty to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this Quarterly Report on Form 10-Q, and you should not rely on statements contained herein as representing our views as of any date subsequent to the date of this Quarterly Report on Form 10-Q.

Unless the context otherwise requires, the terms “LogicBio,” “LogicBio Therapeutics Inc.,” the “Company,” “we,” “us,” “our” and similar references in this Quarterly Report on Form 10-Q refer to LogicBio Therapeutics Inc. and its subsidiaries.

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

LogicBio Therapeutics, Inc.

Condensed Consolidated Balance Sheets

(In thousands, except share and per share data)

(Unaudited)


	March 31,			December 31,
	2019			2018
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	27,870		$	80,906
Short-term investments		44,666			—
Prepaid expenses and other current assets		1,763			1,268

Total current assets		74,299			82,174
Property and equipment, net		880			590
Restricted cash		146			146
Operating lease right-of-use asset		1,259			—
Other assets		57			—

TOTAL ASSETS	$	76,641		$	82,910

LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable	$	1,413		$	1,168
Accrued expenses and other current liabilities		2,354			1,517

Total current liabilities		3,767			2,685
Other liabilities		58			—

Total liabilities		3,825			2,685

STOCKHOLDERS’ EQUITY:
Common stock, par value of $0.0001 per share; 175,000,000 shares authorized as of March 31, 2019 and December 31, 2018, respectively; 22,348,730 and 22,188,393 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively		3			3
Additional paid-in capital		107,749			107,473
Accumulated other comprehensive income (loss)		3			(9	)
Accumulated deficit		(34,939	)		(27,242	)

Total stockholders' equity		72,816			80,225

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	76,641		$	82,910

See notes to consolidated financial statements.

LogicBio Therapeutics, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)

(Unaudited)


	Three Months Ended March 31,
	2019			2018
OPERATING EXPENSES:
Research and development	$	5,486		$	1,455
General and administrative		2,632			918

Total operating expenses		8,118			2,373

LOSS FROM OPERATIONS		(8,118	)		(2,373	)

OTHER INCOME, NET:
Interest income, net		443			68
Other income, net		—			3

Total other income, net		443			71

Loss before income taxes		(7,675	)		(2,302	)
Income tax provision		(22	)		(2	)

Net loss	$	(7,697	)	$	(2,304	)

Net loss attributable to common stockholders—basic and diluted (Note 9)	$	(7,697	)	$	(4,907	)

Net loss per share attributable to common stockholders—basic and diluted	$	(0.34	)	$	(2.75	)

Weighted-average common stock outstanding—basic and diluted		22,313,129			1,787,342

See notes to consolidated financial statements.

LogicBio Therapeutics, Inc.

Condensed Consolidated Statements of Comprehensive Loss

(In thousands)

(Unaudited)


	Three Months Ended March 31,
	2019			2018
Net loss	$	(7,697	)	$	(2,304	)
Other comprehensive income:
Unrealized gain on investments		9			—
Foreign currency translation adjustment		3			7

Comprehensive loss	$	(7,685	)	$	(2,297	)

See notes to consolidated financial statements.

LogicBio Therapeutics, Inc.

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)

(In thousands, except share and per share data)

(Unaudited)


	Convertible Preferred Stock														Accumulated
	Convertible Preferred Stock				Convertible Preferred Stock				Common Stock				Additional		Other						Total
	$0.0001 Par Value Series A				$0.0001 Par Value Series B				$0.0001 Par Value				Paid-in		Comprehensive			Accumulated			Stockholders’
	Shares		Amount		Shares		Amount		Shares		Amount		Capital		(Loss) Income			Deficit			(Deficit) Equity
BALANCE, January 1, 2018		2,976,190	$	4,359		19,541,465	$	28,703		1,606,360	$	1	$	1,035	$	(14	)	$	(9,621	)	$	(8,599	)
Vesting of restricted stock		—		—		—		—		173,717		—		—		—			—			—
Foreign currency translation adjustment		—		—		—		—		—		—		—		7			—			7
Stock-based compensation expense		—		—		—		—		—		—		88		—			—			88
Net loss		—		—		—		—		—		—		—		—			(2,304	)		(2,304	)

BALANCE, March 31, 2018		2,976,190	$	4,359		19,541,465	$	28,703		1,780,077	$	1	$	1,123	$	(7)		$	(11,925	)	$	(10,808	)


BALANCE, January 1, 2019		—	$	—		—	$	—		22,188,393	$	3	$	107,473	$	(9)		$	(27,242	)	$	80,225
Vesting of restricted stock		—		—		—		—		160,337		—		—		—			—			—
Unrealized gain on investments		—		—		—		—		—		—		—		9			—			9
Foreign currency translation adjustment		—		—		—		—		—		—		—		3			—			3
Stock-based compensation expense		—		—		—		—		—		—		276		—			—			276
Net loss		—		—		—		—		—		—		—		—			(7,697	)		(7,697	)

BALANCE, March 31, 2019		—	$	—		—	$	—		22,348,730	$	3	$	107,749	$	3		$	(34,939	)	$	72,816

See notes to consolidated financial statements.

LogicBio Therapeutics, Inc.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)


	Three Months Ended March 31,
	2019			2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(7,697	)	$	(2,304	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		39			9
Net amortization of premiums and discounts on investments		(95	)		—
Stock-based compensation expense		276			88
Non-cash lease expense		274
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		(498	)		50
Other assets		(57	)		(1	)
Accounts payable		201			(670	)
Accrued expenses and other current liabilities		(675	)		(326	)

Net cash used in operating activities		(8,232	)		(3,154	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of investments		(44,562	)		—
Purchase of property and equipment		(247	)		(3	)

Net cash used in investing activities		(44,809	)		(3	)

CASH FLOWS FROM FINANCING ACTIVITIES:

Net cash provided by financing activities		—			—

Effect on foreign exchange rates on cash and cash equivalents		5			7
NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH		(53,036	)		(3,150	)
Cash, cash equivalents and restricted cash at beginning of year		81,052			24,575

Cash, cash equivalents and restricted cash at end of period	$	28,016		$	21,425

RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH
Cash and cash equivalents	$	27,870		$	21,425
Restricted cash		146			—

Total cash, cash equivalents and restricted cash	$	28,016		$	21,425

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for taxes	$	31		$	102

Right-of-use assets obtained in exchange for operating lease obligation	$	1,323		$	—

Property and equipment purchases in accounts payable and accrued expenses	$	81		$	2

See notes to consolidated financial statements.

LogicBio Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

(In thousands, except share and per share data)

(Unaudited).

1. NATURE OF BUSINESS AND BASIS OF PRESENTATION

LogicBio Therapeutics, Inc. (“LogicBio” or the “Company”) was incorporated in 2014 as a Delaware corporation. Its principal offices are in Cambridge, Massachusetts. The Company is a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need, using GeneRide, its proprietary technology platform. GeneRide technology is designed to precisely and stably integrate corrective genes into a patient’s genome to provide a durable therapeutic effect. The Company has demonstrated proof of concept of its therapeutic platform in animal models for a number of diseases and is focusing on its lead product candidate, LB-001, for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth.

On October 23, 2018, the Company completed an initial public offering (“IPO”) in which the Company issued and sold 8,050,000 shares of its common stock, including 1,050,000 shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $10.00 per share, for aggregate gross proceeds of $80,500. The Company received approximately $72,300 in net proceeds after deducting underwriting discounts and commissions and offering costs.

Upon the closing of the IPO, all outstanding shares of convertible preferred stock automatically converted into 11,789,775 shares of common stock at the applicable conversion ratio then in effect. Subsequent to the closing of the IPO, there were no shares of convertible preferred stock outstanding.

Management believes that the Company’s existing cash, cash equivalents and investments will allow the Company to continue its operations through 2020. In the absence of a significant source of recurring revenue, the continued viability of the Company beyond that point is dependent on its ability to continue to raise additional capital to finance its operations. There can be no assurance that the Company will be able to obtain sufficient capital to cover its costs on acceptable terms, if at all.

The accompanying unaudited condensed consolidated financial statements as of March 31, 2019 and for the three months ended March 31, 2019 and 2018 have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on April 1, 2019.

The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments which are necessary for a fair statement of the Company’s financial position as of March 31, 2019, consolidated results of operations for the three months ended March 31, 2019 and 2018 and cash flows for the three months ended March 31, 2019 and 2018. Such adjustments are of a normal and recurring nature. The results of operations for the three months ended March 31, 2019 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2019.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Significant Accounting Policies

The Company’s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on April 1, 2019. Since the date of those financial statements, there have been no material changes to its significant accounting policies other than the Company’s adoption of ASC 842 (defined below) and the Company’s significant accounting policy over investments, both of which are discussed in this note.

Leases

Effective January 1, 2019, the Company adopted ASC Topic 842, Leases (“ASC 842”), using the modified retrospective method and utilized the effective date as its date of initial application, with prior periods presented in accordance with the previous guidance under ASC 840, Leases (“ASC 840”).

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Most leases with a term greater than one year are recognized on the balance sheet as a right-of-use asset and a current and non-current lease liability, as applicable. The Company elected not to recognize on the balance sheet leases with terms of one year or less. The Company typically only includes an initial lease term in its assessment of a leasing arrangement. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew the lease. The Company remeasures and relocates the consideration in a contract when there is a modification of a lease that is not accounted for as a separate contract. A lease modification that results in a separate contract, including when the modification grants the lessee an additional right of use that is not included in the original lease, is accounted for in the same manner as a new lease. The Company monitors its material leases on a quarterly basis.

Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates.

In accordance with ASC 842, components of a lease should be split into three categories: lease components (e.g., land, building, etc.), non-lease components (e.g., common area maintenance, consumables, etc.) and non-components (e.g., property taxes, insurance, etc.). The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.

Although separation of lease and non-lease components is required, certain practical expedients are available. Entities may elect the practical expedient not to separate lease and non-lease components. Rather, entities would account for each lease component and the related non-lease component together as a single component. For new and amended leases beginning in 2019 and after, the Company has elected to account for the lease and non-lease components for leases for classes of all underlying assets together and allocate all of the contract consideration to the lease component only.

Investments

The Company determines the appropriate classification of its investments in debt securities at the time of purchase. All of the Company’s securities are classified as available-for-sale and are reported in short-term investments or long-term investments based on maturity dates and whether such assets are reasonably expected to be realized in cash or sold or consumed during the normal cycle of business. Available-for-sale investments are recorded at fair value, with unrealized gains or losses included in accumulated other comprehensive gain (loss) on the Company’s consolidated balance sheets, exclusive of other-than-temporary impairment losses, if any. Investments may be composed of corporate debt securities, commercial paper, U.S. government and agency securities and certificates of deposit.

Recently Adopted Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, “Leases (Topic 842),” which requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases on their balance sheet date. ASU No. 2016-02 is effective for fiscal years beginning after December 15, 2018. In July 2018, an amendment was made that allows companies the option of using the effective date of the new standard as the initial application date (at the beginning of the period in which the new standard is adopted, rather than at the beginning of the earliest comparative period). This update includes a short-term lease exception for leases with a term of 12 months or less, in which a lessee can make an accounting policy election not to recognize the associated lease assets and lease liabilities on its balance sheet. Additionally, in March 2019, the FASB issued ASU 2019-01, Leases (Topic 842): Codification Improvements (“ASU No. 2019-01”). ASU No. 2019-01 clarifies the transition guidance related to interim disclosures provided in the year of adoption. Lessees will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases, using classification criteria that are substantially similar to the previous guidance. For lessees, the recognition, measurement, and presentation of expenses and cash flows arising from a lease did not significantly change from previous U.S. GAAP. The modified retrospective method includes several optional practical expedients that entities may elect to apply, as well as transition guidance specific to nonstandard leasing transactions. The Company adopted Topic 842 on January 1, 2019 using a cumulative-effect adjustment on the effective date of the standard, for which comparative periods are presented in accordance with the previous guidance under ASC 840.

In adopting Topic 842, the Company elected to utilize the available package of practical expedients permitted under the transition guidance within the new standard, which does not require the reassessment of the following: i) whether existing or expired arrangements are or contain a lease, ii) the lease classification of existing or expired leases, and iii) whether previous initial direct costs would qualify for capitalization under the new lease standard. Additionally, the Company made an accounting policy election to keep leases with a term of 12 months or less off its balance sheet.

Adoption of this standard resulted in the recording of operating lease liabilities and a right-of-use asset of $210 and $210, respectively, on the Company’s condensed consolidated balance sheet on the effective date. The adoption of the standard did not have a material effect on the Company’s condensed consolidated statements of operations and comprehensive loss, condensed consolidated statements of cash flows or accumulated deficit. Refer to note 10 for right-of-use asset and liabilities recorded during the three months ended March 31, 2019.

Recently Issued Accounting Pronouncements

There have been no new accounting pronouncements or changes to accounting pronouncements during the three months ended March 31, 2019, as compared to the recent accounting pronouncements described in Note 2 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, which could be expected to materially impact the Company’s unaudited condensed consolidated financial statements.

3. FAIR VALUE MEASUREMENTS

The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:


			Quoted Prices in		Significant Other		Significant Other
			Active Markets		Observable		Observable
			for Identical		Inputs		Inputs
Description	March 31, 2019		Assets (Level 1)		(Level 2)		(Level 3)
Assets
Sweep bank account	$	2,305	$	2,305	$	—	$	—
Money market funds		24,963		24,963		—		—
U.S. Treasury securities		44,666		44,666		—		—

Total financial assets	$	71,934	$	71,934	$	—	$	—


			Quoted Prices in		Significant Other		Significant Other
			Active Markets		Observable		Observable
			for Identical		Inputs		Inputs
Description	December 31, 2018		Assets (Level 1)		(Level 2)		(Level 3)
Assets
Sweep bank account	$	831	$	831	$	—	$	—
Money market funds		79,212		79,212		—		—

Total financial assets	$	80,043	$	80,043	$	—	$	—

The Company classifies its money market funds and U.S. Treasury securities as Level 1 assets under the fair value hierarchy as these assets have been valued using quoted market prices in active markets without any valuation adjustment.

4. INVESTMENTS

The following table summarizes the Company’s investments, which are considered available-for-sale and were included in short-term investments on the condensed consolidated balance sheet as of March 31, 2019:


	March 31,
	2019
	Cost Basis		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
U.S. Treasury securities	$	44,657	$	9	$	—	$	44,666

Total	$	44,657	$	9	$	—	$	44,666

Certain short-term debt securities with original maturities of less than 90 days are included in cash and cash equivalents on the condensed consolidated balance sheet and are not included in the table above. As of March 31, 2019, all investments have contractual maturities within one year. The Company had no investments as of December 31, 2018.

5. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued expenses and other current liabilities at March 31, 2019 and December 31, 2018 consisted of the following:


	March 31,		December 31,
	2019		2018
Accrued compensation and benefits	$	281	$	709
Accrued professional services		579		585
Lease liabilities		1,201		—
Other		293		223

Total accrued expenses and other current liabilities	$	2,354	$	1,517

Accrued compensation and benefits consists primarily of accrued bonuses and accrued vacation. Accrued professional services consists primarily of consulting services, legal services and services provided by contract research organizations (“CRO”) and contract manufacturing organizations (“CMO”).

6. CONVERTIBLE PREFERRED STOCK

Series A convertible preferred stock and Series B convertible preferred stock is collectively referred to as “Preferred Stock.”

On October 23, 2018, upon the closing of the Company’s IPO, all outstanding shares of Preferred Stock converted into 11,789,775 shares of the Company’s common stock. As such, there were no outstanding shares of Preferred Stock as of March 31, 2019 and December 31, 2018.

The rights and privileges of the preferred stockholders were as follows:

Conversion: Each share of Preferred Stock was convertible, at the option of the holder, at any time, into shares of common stock on a one-for-1.90993 basis. The conversion ratio was determined by dividing the original issue price of $1.4933 by the conversion price of $0.78186. The Preferred Stock would automatically convert into shares of common stock at the closing a Qualified IPO (as defined in the Company’s amended and restated certificate of incorporation, as amended from time to time) or in a non-Qualified IPO, upon the approval of at least 60% of the preferred stockholders.

Liquidation Preference: Prior to the IPO, in the event of any liquidation or “Deemed Liquidation Event,” defined below, the preferred stockholders would have been entitled to the greater of (i) the original issue price of the Preferred Stock plus any accrued dividends not yet paid plus any other dividends declared and unpaid or (ii) the amount payable had all classes of shares been converted to common stock. In the event of a Deemed Liquidation Event, accrued dividends would not exceed 40% of the original issue price. After payments of all preferential amounts are made to the preferred stockholders, any remaining assets would be distributed to the common stockholders on a pro rata basis. A Deemed Liquidation Event was defined as a merger, consolidation, reorganization or similar transaction; the sale transfer, exclusive license of all or substantially all of the Company’s assets/intellectual property; or the sale or transfer of shares to any person (or group of related or affiliated persons), directly or indirectly, representing a greater than 50% of the voting power of the voting securities of the Company.

Dividends: Preferred stockholders were entitled to receive, when and if declared by the board of directors (the “Board”) out of any funds legally available, dividends at the rate of 8% of the original issue price per share. No dividends were declared or paid through October 23, 2018, the date on which all of the Preferred Stock was converted to common stock upon the closing of the Company’s IPO.

Voting Rights: Preferred Stock and common stock voted together as one class on an as converted basis.

7. STOCK-BASED COMPENSATION

Equity Incentive Plans

In December 2014, the Company adopted the LogicBio Therapeutics, Inc. 2014 Equity Incentive Plan, as amended (the “2014 Plan”), for the issuance of stock options and other stock-based awards.

In October 2018, the Company’s 2018 Equity Incentive Plan (the “2018 Plan”) became effective and as a result, no further awards will be made under the 2014 Plan. The 2018 Plan was established to provide equity-based ownership opportunities for employees and directors, as well as outside consultants and advisors. The 2018 Plan authorized up to 1,183,214 of shares of the Company’s common stock to be issued. In addition, any previously granted awards under the 2014 Plan will remain outstanding in accordance with their respective terms.

Under the 2018 Plan, there is an annual increase on January 1 of each year from 2019 until 2028, by the lesser of (i) 4% of the number of shares of common stock outstanding on December 31 of the prior year, and (ii) an amount determined by the Board. On January 1, 2019, the Company increased the number of shares available for future grant under the 2018 Plan. At March 31, 2019, there were 1,286,336 shares available for future grant under the 2018 Plan.

Total stock-based compensation expense recorded as research and development and general and administrative expenses, respectively, for employees, directors and non-employees for the three ended March 31, 2019 and 2018 is as follows:


	Three Months Ended March 31,
	2019		2018
Research and development	$	155	$	48
General and administrative		121		40

Total stock-based compensation expense	$	276	$	88

During the three months ended March 31, 2019 and 2018, the Company granted options to purchase 79,123 and 120,121 shares of common stock, respectively. The Company recorded stock-based compensation expense for options granted of $210 and $31 during the three months ended March 31, 2019 and 2018, respectively.

As of March 31, 2019 and 2018, there were 2,429,562 and 1,521,184 options outstanding, respectively. The weighted-average grant date fair value per share of options granted during the three months ended March 31, 2019 and 2018 was $6.03 and $0.46, respectively. As of March 31, 2019 and 2018, there was $5,003 and $403 of unrecognized stock-based compensation expense related to unvested stock options to be recognized over a period of 2.2 and 2.3 years, respectively.

During the three months ended March 31, 2019 and 2018, the Company did not grant any shares of restricted stock. The Company recorded stock-based compensation expense for restricted stock granted of $66 and $57 during the three months ended March 31, 2019 and 2018, respectively.

As of March 31, 2019 and 2018, there were 724,383 and 1,260,892 shares of unvested restricted stock outstanding, respectively. As of March 31, 2019 and 2018, there was $463 and $344 of unrecognized stock-based compensation expense related to unvested restricted stock to be recognized over a period of 0.7 and 1.6 years, respectively.

8. INCOME TAXES

During the three months ended March 31, 2019 and the year ended December 31, 2018, the Company maintained a full valuation allowance on federal and state deferred tax assets since management does not forecast the Company to be in a profitable position in the near future. The income tax provision within the condensed consolidated statements of operations related to tax expense of the wholly owned foreign subsidiary, LogicBio Therapeutics Research Ltd.

9. LOSS PER SHARE

Basic loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding, without consideration to common stock equivalents:


	Three Months Ended March 31,
	2019			2018
Numerator:
Net loss	$	(7,697	)	$	(2,304	)
Less: accruals of dividends of Preferred Stock		—			(2,603	)

Net loss attributable to common stockholders—basic and diluted	$	(7,697	)	$	(4,907	)

Denominator:
Weighted-average common stock outstanding		22,313,129			1,787,342

Net loss per share attributable to common stockholders—basic and diluted	$	(0.34	)	$	(2.75	)

The Company’s potentially dilutive shares, which include outstanding Preferred Stock and stock options as well as unvested restricted stock, are considered to be common stock equivalents and are only included in the calculation of diluted net loss when their effect is dilutive. The common stock equivalent computation for Preferred Stock uses the applicable conversion rate then in effect for any outstanding shares of Preferred Stock.

The Company excluded the following potential common stock equivalents from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect for the three months ended March 31, 2019 and 2018:


	March 31,		March 31,
	2019		2018
Preferred Stock		—		11,789,775
Unvested restricted stock		724,383		1,260,892
Options to purchase common stock		2,429,562		1,521,184

10. LEASES

The Company has historically entered into lease arrangements for its facilities and certain equipment. As of March 31, 2019, the Company had three operating leases with required future minimum payments. In applying the transition guidance under ASC 842, the Company determined the classification of these leases to be operating leases and recorded a right-of-use asset and lease liabilities as of the effective date. The Company’s leases generally do not include termination or purchase options. From time to time, leases may include options to renew the lease after the expiration of the initial lease term. A renewal period is included in the lease term only when it reasonably certain that the Company will exercise such renewal options. As of March 31, 2019, no renewal options existed that the Company felt were reasonably certain of being exercised.

Operating Leases

In December 2018, the Company entered into an operating lease for laboratory and office space in Cambridge, Massachusetts for a 14-month term, ending in March 2020. As required under the terms of the lease agreement as collateral for the facility lease, the Company had restricted cash of $146 in the form of a certificate deposit as of March 31, 2019 and December 31, 2018.

The following table contains a summary of the lease costs recognized under Topic 842 and other information pertaining to the Company’s operating leases for the three months ended March 31, 2019:


Operating leases	Three Months Ended March 31, 2019
Lease cost
Operating lease cost	$	274
Variable lease cost		42

Total lease cost	$	316


Other quarterly lease information
Operating cash flows used for operating leases	$	199
Operating lease liabilities arising from obtaining right-of-use assets	$	1,323

Other operating lease information	As of March 31, 2019
Operating lease liabilities—short term	$	1,201
Operating lease liabilities—long term	$	58
Weighted average remaining lease term		1.1 years
Weighted average discount rate		7.04	%

The variable lease costs for the quarter ended March 31, 2019 include common area maintenance and other operating charges. As the Company’s leases do not provide an implicit rate, the Company utilized its incremental borrowing rate based on what we would normally pay to borrow on a collateralized basis over a similar term for an amount equal to the lease payments at the commencement date in determining the present value of lease payments. As of March 31, 2019, the Company classified its short term and long term operating lease liabilities within accrued expenses and other current liabilities and other liabilities, respectively.

Future minimum lease payments under the Company’s operating leases as of March 31, 2019 and December 31, 2018, were as follows:


Maturity of lease liabilities	As of		As of
(in thousands)	December 31, 2018		March 31, 2019
2019	$	1,028	$	936
2020		223		377
Thereafter		—		—

Total lease payments	$	1,251	$	1,313
Less: imputed interest				(54	)

Total operating lease liabilities at March 31, 2019			$	1,259

11. RELATED PARTIES

From time to time, the Company is or has been party to consulting service agreements with each of its three founders. Under the terms of each agreement, the Company pays an annual fee of $68 for research and development consulting services. For the three months ended March 31, 2019 and 2018, the Company has made payments totaling $51 and $34, respectively, under these consulting service agreements. In addition, each founder receives $5 annually for their participation on the scientific advisory board (the “SAB”), beginning in 2018. Each founder has also received stock options for their services as either a member of the Board or member of the SAB.

In March 2017, the Company subleased to an affiliate certain space in Tel Aviv, Israel, through June 2018. For the three months ended March 31, 2018, the Company recognized income of $13 in other income, net.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial information and the notes thereto included in this Quarterly Report on Form 10-Q and the audited consolidated financial information and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018, which was filed with the Securities and Exchange Commission, or SEC, on April 1, 2019.

This discussion contains certain forward-looking statements that involve risks and uncertainties. Forward-looking statements are identified by words such as “believe,” “will,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “could,” “potentially” or the negative of these terms or similar expressions. You should read these statements carefully because they discuss future expectations, contain projections of future results of operations or financial condition, or state other “forward-looking” information. These statements relate to our future plans, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in the “Risk Factors” section in this Quarterly Report on Form 10-Q. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. These statements, like all statements in this Quarterly Report on Form 10-Q, speak only as of their date, and except as required by law, we undertake no obligation to update or revise these statements in light of future developments. We caution investors that our business and financial performance are subject to substantial risks and uncertainties.

Overview

We are a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need using GeneRide, our proprietary technology platform. Our GeneRide technology is designed to precisely integrate corrective genes into a patient’s genome to provide a stable therapeutic effect. Because GeneRide is designed to have this durable therapeutic effect, we are initially targeting rare liver disorders in pediatric patients where it is critical to provide treatment early in a patient’s life before irreversible disease pathology can occur. We have demonstrated proof of concept of our therapeutic platform in animal models for a number of diseases and are focusing on development of our lead product candidate, LB-001, for the treatment of Methylmalonic Acidemia, or MMA, a life-threatening disease that presents at birth.

Based on our GeneRide technology, we are developing our lead product candidate, LB-001, to treat MMA. We plan to advance LB-001 to an IND filing by the end of 2019 and into a Phase 1/2 clinical trial in pediatric MMA patients in 2020. We believe that achieving clinical proof of concept in an inherited liver disease such as MMA will validate our platform technology, including its potential application to other organs and diseases. In addition to MMA, we have demonstrated proof of concept of our platform in hemophilia B, alpha-1-antitrypsin deficiency, or A1ATD, and Crigler-Najjar syndrome animal disease models. We expect to select future product candidates from these genetic diseases or others addressed by targeting the liver initially, and later by targeting the central nervous system and muscle.

Since our inception in 2014, we have devoted the majority of our efforts to business planning, research and development, developing and protecting our intellectual property, raising capital and recruiting management and technical staff. We do not have any products approved for sale and have not generated any revenue. As of March 31, 2019, we have raised approximately $72.3 million in net proceeds through our initial public offering, or IPO, in October 2018 and approximately $33.1 million in net proceeds from the sale of our convertible preferred stock in 2016 and 2017. We have incurred significant operating losses since our inception. Our ability to generate product revenue sufficient to achieve profitability will depend on the successful development and commercialization of our product candidate and any future product candidates. Our net loss was $7.7 million for the three months ended March 31, 2019 and our accumulated deficit was $34.9 million as of March 31, 2019. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future in connection with our ongoing activities. Furthermore, we expect to incur additional costs associated with operating as a public company that we did not previously incur or had previously incurred at lower rates as a private company, including significant legal, accounting, investor relations and other expenses.

Components of Results of Operations

Revenue

Since inception through March 31, 2019, we have not generated any revenue. We do not expect to generate any revenue from the sale of products in the near future. If our development efforts for LB-001, or other product candidates that we may develop in the future, are successful and result in regulatory approval or collaboration or license agreements with third parties, we may generate revenue in the future from a combination of product sales or payments from collaboration or license agreements.

Operating Expenses

Research and Development Expenses

Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts and the development of our product candidates, and include:

•

salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions;

•

license maintenance fees and milestone fees incurred in connection with various license agreements;

•

the cost of laboratory supplies and acquiring, developing and manufacturing preclinical study and, eventually, clinical trial materials;

•

expenses incurred under agreements with contract research organizations, or CROs, contract manufacturing organizations, or CMOs, as well as academic institutions and consultants that conduct our preclinical studies and other scientific development services;

•

facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs;

•

costs of outside consultants, including their fees, stock-based compensation and related travel expenses; and

•

costs related to compliance with regulatory requirements.

We expense research and development costs as incurred. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our financial statements as prepaid or accrued research and development expenses.

Research and development activities are central to our business model. We expect that our research and development expenses will continue to increase for the foreseeable future as we plan and initiate clinical trials for our product candidate LB-001 and continue to discover and develop additional product candidates. If any of our product candidates enter into later stages of clinical development, they will generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive, finance, corporate and business development and administrative functions. General and administrative expenses also include professional fees for legal, patent, accounting, auditing, tax and consulting services, travel expenses, and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.

We expect that our general and administrative expenses will increase in the future as we increase our general and administrative headcount to support our continued research and development and potential commercialization of our product candidates. We also expect to continue to incur increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory and tax compliance services, director and officer insurance costs; and investor and public relations costs.

Other Income, Net

Interest income, net consists primarily of interest on our cash and cash equivalents and investments. Other income, net consists primarily of foreign exchange gains and losses.

Results of Operations

Three Months Ended March 31, 2019 and 2018

The following table summarizes our results of operations for the three months ended March 31, 2019 and 2018:


	Three Months Ended
	March 31,
	2019			2018
	*(in thousands)*
Operating expenses:
Research and development	$	5,486		$	1,455
General and administrative		2,632			918

Total operating expenses		8,118			2,373

Loss from operations		(8,118	)		(2,373	)

Other income:
Other income, net		443			71

Loss before income taxes		(7,675	)		(2,302	)
Income tax provision		(22	)		(2	)

Net loss	$	(7,697	)	$	(2,304	)

Research and Development Expenses

The following table summarizes our research and development expenses for the three months ended March 31, 2019 and 2018:


	Three Months Ended
	March 31,
	2019		2018		Increase
			*(in thousands)*
LB-001 external development and manufacturing costs	$	2,754	$	494		2,260
Personnel-related costs		1,197		512		685
Other research and development costs		1,535		449		1,086

Total research and development expenses	$	5,486	$	1,455	$	4,031

Research and development expenses for the three months ended March 31, 2019 were $5.5 million, compared to $1.5 million for the three months ended March 31, 2018. The increase of approximately $4.0 million was primarily due to an increase of approximately $2.3 million related to external development and manufacturing expenses for our lead product candidate LB-001, $1.1 million in other research and development expenses as we increased our overall research and development activities related to general platform development and internal efforts for our lead product candidate LB-001 and $0.7 million in personnel-related costs related to an increase in headcount. Personnel-related costs for the three months ended March 31, 2019 included stock-based compensation expense of $0.2 million, compared to $48,000 for the three months ended March 31, 2018.

General and Administrative Expenses

General and administrative expenses were $2.6 million for the three months ended March 31, 2019, compared to $0.9 million for the three months ended March 31, 2018. The increase of approximately $1.7 million was primarily due to professional fees and personnel-related costs, including salaries, stock-based compensation and bonuses. The increase in professional fees was primarily due to the increase in legal, auditing and consulting services provided. The increase in personnel-related costs was primarily due to an increase in headcount of executive level employees. Stock-based compensation expense included in general and administrative expenses was $0.1 million and $40,000 for the three months ended March 31, 2019 and 2018, respectively.

Other Income, Net

Other income, net was $0.4 million for the three months ended March 31, 2019, compared to other income, net of $0.1 million for the three months ended March 31, 2018. The change was primarily related to the increase in interest income from cash equivalents and investments.

Liquidity and Capital Resources

Overview

Since our inception and through March 31, 2019, we have not generated any revenue and have incurred significant losses and negative cash flows from our operations.

Cash Flows

The following table summarized our cash flows for each of the three months ended March 31, 2019 and 2018:


	Three Months Ended March 31,
	2019			2018
	*(in thousands)*
Net cash used in operating activities	$	(8,232	)	$	(3,154	)
Net cash used in investing activities		(44,809	)		(3	)
Net cash provided by financing activities		—			—
Effect on foreign exchange rates on cash and cash equivalents		5			7

Net decrease in cash and cash equivalents	$	(53,036	)	$	(3,150	)

Operating Activities

The net cash used in operating activities in both periods resulted primarily from our net losses adjusted for non-cash charges and changes in the components of working capital. The increase in cash used in operating activities during the three months ended March 31, 2019 compared to the three months ended March 31, 2018, was primarily driven by an increase in our net loss due to an increase in both our research and development and general and administrative expenses.

Investing Activities

During the three months ended March 31, 2019, net cash used in investing activities increased approximately $44.8 million, primarily related to our purchase of investment securities of $44.6 million and a $0.2 million increase in the purchases of property and equipment as compared to the three months ended March 31, 2018.

Financing Activities

During the three months ended March 31, 2019 and 2018, there were no net cash inflows or outflows related to financing activities.

Funding Requirements

We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials of our product candidate and any future product candidates. We expect that our expenses will increase substantially if and as we:

•

continue our current research programs and our preclinical development of any product candidates from our current research programs;

•

initiate clinical trials for LB-001 and any other product candidates we identify and develop;

•

seek to identify, assess, acquire and/or develop additional research programs and additional product candidates;

•

seek marketing approvals for any product candidate that successfully complete clinical trials;

•

develop, optimize, scale and validate a manufacturing process and analytical methods for any product candidates we may develop;

•

establish and build out internal process and analytical development capabilities and research and preclinical grade production;

•

obtain market acceptance of any product candidates we may develop as viable treatment options;

•

address competing technological and market developments;

•

maintain, expand and protect our intellectual property portfolio and provide reimbursement of third-party expenses related to our patent portfolio;

•

further develop our GeneRide technology platform;

•

hire additional technical, quality, regulatory, clinical, scientific and commercial personnel and add operational, financial and management information systems and personnel, including personnel to support our process and product development, manufacturing and planned future commercialization efforts;

•

make royalty, milestone or other payments under current and any future in-license agreements;

•

establish and maintain supply chain and manufacturing relationships with third parties that can provide adequate products and services, in both amount, timing and quality, to support clinical development and the market demand for any product candidate for which we obtain regulatory and marketing approval;

•

leasing and building new facilities, including offices and labs, to support organizational growth;

•

validate and build-out a commercial-scale current Good Manufacturing Practices, or cGMP, manufacturing facility; and

•

establish a sales, marketing and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval.

Because of the numerous risks and uncertainties associated with the development of LB-001 and any other product candidates and programs we may develop, and because the extent to which we may enter into collaborations with third parties for development of LB-001 and any other product candidates we may develop is unknown, we are unable to estimate the timing and amounts of increased capital outlays and operating expenses associated with completing the research and development of our product candidates. Our future funding requirements, both near and long-term, will depend on many factors, including:

•

the initiation, scope, progress, timing, costs and results of drug discovery, preclinical development, laboratory testing, and planned clinical trials for LB-001 and any other product candidates;

•

the outcome, timing and cost of meeting regulatory requirements established by the U.S. Food and Drug Administration, or FDA, and other comparable foreign regulatory authorities, including resolving any potential clinical holds that may be imposed on us;

•

the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;

•

the cost of defending potential intellectual property disputes, including patent infringement actions;

•

the achievement of milestones or occurrence of other developments that trigger payments under any of our current agreements or other agreements we may enter into;

•

the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under future collaboration agreements, if any;

•

the effect of competing technological and market developments;

•

the cost and timing of completion of clinical or commercial-scale manufacturing activities;

•

the extent to which we in-license or acquire other products and technologies;

•

our ability to establish and maintain collaborations on favorable terms, if at all;

•

the cost of establishing sales, marketing and distribution capabilities for LB-001 and any other product candidates in regions where we choose to commercialize our product candidates, if approved; and

•

the initiation, progress, timing and results of our commercialization of LB-001 and any other product candidates, if approved, for commercial sale.

A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant trial delays due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development. We may never succeed in obtaining regulatory approval for our product candidate or any future product candidates.

Until such time, if ever, that we can generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through offerings of securities, private equity financing, debt financings, collaborations, government contracts or other strategic transactions. The terms of financing may adversely affect the holdings or the rights of our stockholders. If we are unable to obtain funding, we may be required to delay, limit, reduce or terminate some or all of our research and product development, product portfolio expansion or future commercialization efforts.

We will also continue to incur costs as a public company that we did not previously incur or have previously incurred at lower rates, including increased fees payable to the non-employee members of our board of directors, increased personnel costs, increased director and officer insurance premiums, audit and legal fees, investor relations fees and expenses for compliance with public company reporting requirements under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and rules implemented by the SEC and Nasdaq.

Contractual Obligations and Commitments

The following table summarizes our contractual obligations as of March 31, 2019:


	Payments Due by Period
	Total		Less than 1 Year		1 to 3 Years		4 to 5 Years		More than 5 Years
	*(in thousands)*
Operating lease commitments	$	1,313	$	936	$	377	$	—	$	—
Collaboration and research agreements (1)		559		559		—		—		—

Total	$	1,872	$	1,495	$	377	$	—	$	—

(1)

Represents license and research fees under our collaboration and research agreements. These amounts do not include any potential contingent payments, including those due upon the achievement by us of specified clinical, regulatory and commercial events, as applicable, or patent prosecution, royalty payments or license and research fees we may be required to make under license agreements we have entered into with various entities, including Stanford, the University of Texas and other research institutions. We have excluded these potential payments in the contractual obligations table because the timing and likelihood of these contingent payments are not currently known and would be difficult to predict or estimate.

We enter into contracts in the normal course of business with CROs, CMOs and other third parties for preclinical research studies and testing. Manufacturing commitments in the preceding table include agreements that are enforceable and legally binding on us and that specify all significant terms, including fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. For obligations with cancellation provisions, the amounts included in the preceding table are limited to the non-cancelable portion of the agreement terms or the minimum cancellation fee.

We may incur potential contingent payments upon our achievement of clinical, regulatory and commercial milestones, as applicable, or royalty payments that we may be required to make under license agreements we have entered into with various entities pursuant to which we have in-licensed certain intellectual property. Due to the uncertainty of the achievement and timing of the events requiring payment under these agreements, the amounts to be paid by us are not fixed or determinable at this time and are excluded from the table above.

Critical Accounting Policies and Significant Judgments and Estimates

Our condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

There have been no significant changes to our critical accounting policies from those described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” included in our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on April 1, 2019.

Emerging Growth Company Status

The Jumpstart Our Business Startups Act of 2012 permits an “emerging growth company” such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have irrevocably elected to “opt out” of this provision and, as a result, we will comply with new or revised accounting standards when they are required to be adopted by public companies that are not emerging growth companies.

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements and do not have any holdings in variable interest entities.

Recently Issued Accounting Pronouncements

Refer to Note 2, in the accompanying notes to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q for a discussion of recent accounting pronouncements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities and foreign currency exchange rate sensitivities.

Interest Rate Sensitivity

As of March 31, 2019, we had cash, cash equivalents and investments of $72.5 million. Our exposure to interest rate sensitivity is impacted by changes in the underlying U.S. bank interest rates. From time to time, our surplus cash has been invested in interest-bearing savings accounts and U.S. government and agency securities. We have not entered into investments for trading or speculative purposes. Due to the conservative nature of our investment portfolio, which is predicated on capital preservation of investments with short-term maturities, we do not believe an immediate one percentage point change in interest rates would have a material effect on the fair market value of our portfolio, and therefore we do not expect our operating results or cash flows to be significantly affected by changes in market interest rates.

As of March 31, 2019, we had no debt outstanding and are therefore not subject to interest rate risk related to debt.

Foreign Currency Exchange Risk

The functional currency of our wholly owned foreign subsidiary, LogicBio Therapeutics Research Ltd, or LogicBio Research, is the Israeli new shekel. Assets and liabilities of LogicBio Research are translated into United States dollars at the exchange rate in effect on the consolidated balance sheet date. Income items and expenses are translated at the average exchange rate in effect during the period. Stockholders’ equity (deficit) amounts are translated based on historical exchange rates as of the date of each transaction. Unrealized translation gains and losses are recorded as a foreign currency translation adjustment, which is included in the consolidated statements of convertible preferred stock and stockholder’s deficit as a component of accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other (expense) income, net in the consolidated statements of operations as incurred. All operations have ceased for LogicBio Research as of September 30, 2018.

We do not currently engage in currency hedging activities in order to reduce our currency exposure, but we may begin to do so in the future. Instruments that may be used to hedge future risks include foreign currency forward and swap contracts. These instruments may be used to selectively manage risks, but there can be no assurance that we will be fully protected against material foreign currency fluctuations.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of March 31, 2019. Our disclosure controls and procedures are designed to ensure that information we are required to disclose in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures, and is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms.

Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of March 31, 2019 were not effective due to the material weakness identified in fiscal year 2017 in our internal control over financial reporting process which included an ineffective control environment, including a lack of sufficient accounting personnel and personnel with financial reporting expertise, ineffective controls procedures, including those related to recognition in the appropriate period for certain transactions, ineffective risk assessment controls, including those policies and practices that would identify changes in our business practices, which could significantly impact our consolidated financial statements and system of internal controls, and ineffective monitoring of controls related to the financial close and reporting process.

Remediation Plan

We are committed and are taking steps necessary to remediate the control deficiencies that constituted the above material weakness by implementing changes to our internal control over financial reporting. During 2018 and through March 31, 2019, we made the following enhancements to our control environment including the following:

•

We added finance personnel to the organization to strengthen our internal accounting team to include a controller.

•

We engaged a third party to help us enhance our documentation of accounting policies and positions on technical accounting topics throughout the year.

•

We engaged outside consultants to assist in the design, implementation, and documentation of internal controls that address the relevant risks, are properly designed, and provide for appropriate evidence of performance of the internal control.

•

We engaged outside consultants to assist us in the evaluation of our information systems to determine if there are internal control gaps that should be addressed in the general information technology controls and implement any needed improvements for existing systems.

Our remediation activities are continuing through the remainder of 2019. In addition to the above activities, we expect to engage in additional activities in the current year, including:

•

Add more accounting resources to enhance our control environment;

•

Continue to engage external consultants to provide support related to more complex applications of GAAP and document and assess our accounting policies and procedures;

•

Enhance the execution of our risk assessment activities by evaluating whether the design of our internal controls appropriately address changes in the business and that could impact our system of internal controls; and

•

Engage outside consultants to perform tests of our system of internal controls to monitor the operating effectiveness of operation of our internal controls and to gain assurance whether such controls are present and functioning.

We continue to redesign and implement internal control activities. We continue to establish policies and procedures and enhance corporate oversight over process-level controls and structures to ensure that there is appropriate assignment of authority, responsibility, and accountability to enable remediating our material weaknesses.

We believe that our remediation plan will be sufficient to remediate the identified material weakness and strengthen our internal control over financial reporting. As we continue to evaluate, and work to improve, our internal control over financial reporting, management may determine that additional measures to address control deficiencies or modifications to the remediation plan are necessary. We cannot assure you, however, when we will remediate such weaknesses, nor can it be certain whether additional actions will be required or the costs of any such actions. Moreover, we cannot assure you that additional material weaknesses will not arise in the future.

Changes in Internal Control over Financial Reporting.

Except for the remediation efforts of the previously identified material weakness as described above, there were no changes in our internal control over financial reporting that occurred during the three months ended March 31, 2019 that materially affected, or were reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may become involved in legal proceedings and claims arising in the ordinary course of our business. Although the results of litigation and claims cannot be predicted with certainty, as of the end of the period covered by this Quarterly Report on Form 10-Q, we did not believe we were party to any claim or litigation, the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Item 1A. Risk Factors.

There have been no material changes from the risk factors previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed with the SEC on April 1, 2019.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds From Sales of Registered Securities.

Use of Proceeds From Registered Securities

On October 23, 2018, we closed our IPO, in which we issued and sold 8,050,000 shares of our common stock, including 1,050,000 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $10.00 per share for gross proceeds of $80.5 million, before deducting underwriting discounts and commissions and offering expenses payable by us. All of the shares issued and sold in the IPO were registered under the Securities Act pursuant to a Registration Statement on Form S-1 (File No. 333-227523), which was declared effective by the SEC on October 18, 2018. Jefferies LLC, Barclays Capital Inc. and William Blair & Company, L.L.C. acted as joint book-running managers of the offering and as representatives of the underwriters. Chardan Capital Markets, LLC acted as the lead manager for the offering. The offering commenced on October 18, 2018 and did not terminate until the sale of all of the shares offered.

The net offering proceeds to us, after deducting underwriting discounts and offering costs payable by us of an aggregate of approximately $8.2 million, were approximately $72.3 million. No material offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning 10.0% or more of any class of our equity securities or to any other affiliates.

There has been no material change in our planned use of the net offering proceeds from our IPO as described in our final prospectus filed with the SEC pursuant to Rule 424(b)(4) on October 18, 2018. As of March 31, 2019, we consumed approximately $13.8 million of net proceeds from the IPO, primarily to continue ongoing development of LB-001 in MMA and for discovery and preclinical development of additional product candidates, and for working capital and general corporate purposes. We invested the remaining funds received in cash equivalents and investments.

Item 6. Exhibits.



EXHIBIT 3.1	—	Fourth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed on October 29, 2018).

EXHIBIT 3.2	—	Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K, filed on October 29, 2018).

EXHIBIT 31.1	—	Rule 13a—14(a) / 15d—14(a) Certifications — Chief Executive Officer.

EXHIBIT 31.2	—	Rule 13a—14(a) / 15d—14(a) Certifications — Chief Financial Officer.

EXHIBIT 32.1	—	Section 1350 Certifications.

EXHIBIT 101.INS	—	XBRL Instance Document.

EXHIBIT 101.SCH	—	XBRL Taxonomy Extension Schema Document.

EXHIBIT 101.CAL	—	XBRL Taxonomy Extension Calculation Linkbase Document.

EXHIBIT 101.DEF	—	XBRL Taxonomy Extension Definition Linkbase Document.

EXHIBIT 101.LAB	—	XBRL Taxonomy Extension Label Linkbase Document.

EXHIBIT 101.PRE	—	XBRL Taxonomy Extension Presentation Linkbase Document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	LogicBio Therapeutics, Inc.

Dated: May 14, 2019	By:	/s/ Frederic Chereau
		Frederic Chereau
		President and Chief Executive Officer

Dated: May 14, 2019	By:	/s/ Matthias Jaffé
		Matthias Jaffé
		Chief Financial Officer

EX-31.1 2 d730342dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a)

and 15d-14(a), as adopted pursuant to Section 302 of Sarbanes-Oxley Act of 2002

I, Frederic Chereau, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of LogicBio Therapeutics, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report), that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Frederic Chereau

Frederic Chereau

President and Chief Executive Officer

Dated: May 14, 2019

EX-31.2 3 d730342dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a)

and 15d-14(a), as adopted pursuant to Section 302 of Sarbanes-Oxley Act of 2002

I, Matthias Jaffé, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of LogicBio Therapeutics, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Matthias Jaffé

Matthias Jaffé

Chief Financial Officer

Dated: May 14, 2019

EX-32.1 4 d730342dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT

TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of LogicBio Therapeutics, Inc. (the “Company”) for the quarter ended March 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the company, hereby certifies, pursuant to Section 1350 of Chapter 63 of Title 18, United States Code, that to the best of his knowledge:

(1)

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated: May 14, 2019		/s/ Frederic Chereau
		Frederic Chereau President and Chief Executive Officer

Dated: May 14, 2019		/s/ Matthias Jaffé
		Matthias Jaffé Chief Financial Officer

EX-101.INS 5 logc-20190331.xml XBRL INSTANCE DOCUMENT

1183214

22494299

21425000

-10808000

403000

1521184

344000

1260892

28703000

19541465

4359000

2976190

1123000

-7000

1000

1780077

-11925000

11789775

10.00

2354000

74299000

579000

107749000

1413000

3000

76641000

9000

44657000

44666000

27870000

28016000

175000000

22348730

0.0001

22348730

3000

281000

3767000

377000

936000

54000

3825000

76641000

1313000

P1Y1M6D

58000

1259000

1201000

58000

1259000

57000

0.0704

293000

880000

1763000

-34939000

146000

72816000

44666000

1.4933

72816000

2354000 0.78186 0.5235

210000

5003000

2429562

463000

724383

24963000

2305000

71934000

44666000

71934000

44666000

9000

44657000

44666000

1286336

107749000

3000

22348730

-34939000

24575000

-8599000

28703000

19541465

4359000

2976190

1035000

-14000

1000

1606360

-9621000

1517000

82174000

585000

107473000

1168000

-9000

82910000

80906000

81052000

175000000

22188393

0.0001

22188393

3000

709000

2685000

223000

1028000

2685000

82910000

1251000

223000

590000

1268000

-27242000

146000

80225000

1517000

79212000

831000

80043000

107473000

-9000

3000

22188393

-27242000

P14M

1050000

80500000

8050000

72300000 2018-06 2020-03

0.04

5000

88000

2000

-3150000

-2297000

9000

-2.75

7000

918000

-2302000

2000

-670000

-326000

-50000

102000

68000

1000

71000

-3000

-3154000

-2304000

3000

7000

2373000

-2373000

3000

-2304000

1455000

88000

1787342

-4907000 -2603000

1521184000

11789775000

1260892000

P2Y3M18D

0.46

31000

57000

P1Y7M6D

40000

48000

88000

120121

34000

88000

7000

173717

-2304000

13000

<div> 5. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities at March 31, 2019 and December 31, 2018 consisted of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2019</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accrued compensation and benefits </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">281</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">709</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accrued professional services </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">579</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">585</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Lease liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,201</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">293</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">223</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total accrued expenses and other current liabilities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,354</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,517</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Accrued compensation and benefits consists primarily of accrued bonuses and accrued vacation. Accrued professional services consists primarily of consulting services, legal services and services provided by contract research organizations (“CRO”) and contract manufacturing organizations (“CMO”). </div>

false

276000

95000

<div> 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION LogicBio Therapeutics, Inc. (“LogicBio” or the “Company”) was incorporated in 2014 as a Delaware corporation. Its principal offices are in Cambridge, Massachusetts. The Company is a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need, using GeneRide, its proprietary technology platform. GeneRide technology is designed to precisely and stably integrate corrective genes into a patient’s genome to provide a durable therapeutic effect. The Company has demonstrated proof of concept of its therapeutic platform in animal models for a number of diseases and is focusing on its lead product candidate, LB-001, for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. On October 23, 2018, the Company completed an initial public offering (“IPO”) in which the Company issued and sold 8,050,000 shares of its common stock, including 1,050,000 shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $10.00 per share, for aggregate gross proceeds of $80,500. The Company received approximately $72,300 in net proceeds after deducting underwriting discounts and commissions and offering costs. Upon the closing of the IPO, all outstanding shares of convertible preferred stock automatically converted into 11,789,775 shares of common stock at the applicable conversion ratio then in effect. Subsequent to the closing of the IPO, there were no shares of convertible preferred stock outstanding. Management believes that the Company’s existing cash, cash equivalents and investments will allow the Company to continue its operations through 2020. In the absence of a significant source of recurring revenue, the continued viability of the Company beyond that point is dependent on its ability to continue to raise additional capital to finance its operations. There can be no assurance that the Company will be able to obtain sufficient capital to cover its costs on acceptable terms, if at all. The accompanying unaudited condensed consolidated financial statements as of March 31, 2019 and for the three months ended March 31, 2019 and 2018 have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on April 1, 2019. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments which are necessary for a fair statement of the Company’s financial position as of March 31, 2019, consolidated results of operations for the three months ended March 31, 2019 and 2018 and cash flows for the three months ended March 31, 2019 and 2018. Such adjustments are of a normal and recurring nature. The results of operations for the three months ended March 31, 2019 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2019. </div>

81000

<div> Significant Accounting Policies The Company’s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on April 1, 2019. Since the date of those financial statements, there have been no material changes to its significant accounting policies other than the Company’s adoption of ASC 842 (defined below) and the Company’s significant accounting policy over investments, both of which are discussed in this note. </div>

-53036000

-7685000

<div> The following table summarizes the Company’s investments, which are considered available-for-sale and were included in short-term investments on the condensed consolidated balance sheet as of March 31, 2019:   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="14" align="center">March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center">2019</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Cost Basis</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross Unrealized Gains</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross Unrealized Losses</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Fair Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> U.S. Treasury securities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,657</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 9</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right">  —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,666</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,657</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,666</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

--12-31

<div> 7. STOCK-BASED COMPENSATION Equity Incentive Plans In December 2014, the Company adopted the LogicBio Therapeutics, Inc. 2014 Equity Incentive Plan, as amended (the “2014 Plan”), for the issuance of stock options and other stock-based awards. In October 2018, the Company’s 2018 Equity Incentive Plan (the “2018 Plan”) became effective and as a result, no further awards will be made under the 2014 Plan. The 2018 Plan was established to provide equity-based ownership opportunities for employees and directors, as well as outside consultants and advisors. The 2018 Plan authorized up to 1,183,214 of shares of the Company’s common stock to be issued. In addition, any previously granted awards under the 2014 Plan will remain outstanding in accordance with their respective terms.   Under the 2018 Plan, there is an annual increase on January 1 of each year from 2019 until 2028, by the lesser of (i) 4% of the number of shares of common stock outstanding on December 31 of the prior year, and (ii) an amount determined by the Board. On January 1, 2019, the Company increased the number of shares available for future grant under the 2018 Plan. At March 31, 2019, there were 1,286,336 shares available for future grant under the 2018 Plan. Total stock-based compensation expense recorded as research and development and general and administrative expenses, respectively, for employees, directors and non-employees for the three ended March 31, 2019 and 2018 is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="81%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2019</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">155</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">48</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">121</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">40</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total stock-based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">276</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">88</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> During the three months ended March 31, 2019 and 2018, the Company granted options to purchase 79,123 and 120,121 shares of common stock, respectively. The Company recorded stock-based compensation expense for options granted of $210 and $31 during the three months ended March 31, 2019 and 2018, respectively. As of March 31, 2019 and 2018, there were 2,429,562 and 1,521,184 options outstanding, respectively. The weighted-average grant date fair value per share of options granted during the three months ended March 31, 2019 and 2018 was $6.03 and $0.46, respectively. As of March 31, 2019 and 2018, there was $5,003 and $403 of unrecognized stock-based compensation expense related to unvested stock options to be recognized over a period of 2.2 and 2.3 years, respectively. During the three months ended March 31, 2019 and 2018, the Company did not grant any shares of restricted stock. The Company recorded stock-based compensation expense for restricted stock granted of $66 and $57 during the three months ended March 31, 2019 and 2018, respectively. As of March 31, 2019 and 2018, there were 724,383 and 1,260,892 shares of unvested restricted stock outstanding, respectively. As of March 31, 2019 and 2018, there was $463 and $344 of unrecognized stock-based compensation expense related to unvested restricted stock to be recognized over a period of 0.7 and 1.6 years, respectively. </div>

Q1 2019 10-Q

39000

-0.34

<div> 9. LOSS PER SHARE Basic loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding, without consideration to common stock equivalents:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2019</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Numerator: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Net loss </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(7,697</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,304</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Less: accruals of dividends of Preferred Stock </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,603</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Net loss attributable to common stockholders—basic and diluted </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(7,697</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(4,907</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Denominator: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Weighted-average common stock outstanding </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,313,129</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,787,342</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Net loss per share attributable to common stockholders—basic and diluted </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.34</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2.75</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The Company’s potentially dilutive shares, which include outstanding Preferred Stock and stock options as well as unvested restricted stock, are considered to be common stock equivalents and are only included in the calculation of diluted net loss when their effect is dilutive. The common stock equivalent computation for Preferred Stock uses the applicable conversion rate then in effect for any outstanding shares of Preferred Stock.   The Company excluded the following potential common stock equivalents from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect for the three months ended March 31, 2019 and 2018:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2019</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Preferred Stock </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,789,775</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Unvested restricted stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">724,383</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,260,892</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Options to purchase common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,429,562</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,521,184</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> </div>

5000

0001664106 LogicBio Therapeutics, Inc. true

<div> 3. FAIR VALUE MEASUREMENTS The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="44%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Quoted Prices in</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Significant Other</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Significant Other</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Active Markets</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Observable</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Observable</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">for Identical</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Inputs</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Inputs</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom" nowrap="nowrap"> Description </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2019</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Assets (Level 1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">(Level 2)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">(Level 3)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Sweep bank account </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,305</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,305</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right">—</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Money market funds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24,963</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24,963</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> U.S. Treasury securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44,666</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44,666</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total financial assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">71,934</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">71,934</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right">—</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Quoted Prices in</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Significant Other</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Significant Other</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Active Markets</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Observable</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Observable</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">for Identical</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Inputs</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Inputs</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom" nowrap="nowrap"> Description </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Assets (Level 1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">(Level 2)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">(Level 3)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Sweep bank account </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">831</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">831</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Money market funds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">79,212</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">79,212</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total financial assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">80,043</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">80,043</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The Company classifies its money market funds and U.S. Treasury securities as Level 1 assets under the fair value hierarchy as these assets have been valued using quoted market prices in active markets without any valuation adjustment. </div>

2019-03-31 true true Non-accelerated Filer

2632000

-7675000

22000

201000

-675000

498000

<div> 8. INCOME TAXES During the three months ended March 31, 2019 and the year ended December 31, 2018, the Company maintained a full valuation allowance on federal and state deferred tax assets since management does not forecast the Company to be in a profitable position in the near future. The income tax provision within the condensed consolidated statements of operations related to tax expense of the wholly owned foreign subsidiary, LogicBio Therapeutics Research Ltd. </div>

31000

<div> Investments The Company determines the appropriate classification of its investments in debt securities at the time of purchase. All of the Company’s securities are classified as available-for-sale and are reported in short-term investments or long-term investments based on maturity dates and whether such assets are reasonably expected to be realized in cash or sold or consumed during the normal cycle of business. Available-for-sale investments are recorded at fair value, with unrealized gains or losses included in accumulated other comprehensive gain (loss) on the Company’s consolidated balance sheets, exclusive of other-than-temporary impairment losses, if any. Investments may be composed of corporate debt securities, commercial paper, U.S. government and agency securities and certificates of deposit. </div>

443000

57000

316000

<div> 4. INVESTMENTS The following table summarizes the Company’s investments, which are considered available-for-sale and were included in short-term investments on the condensed consolidated balance sheet as of March 31, 2019:   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="14" align="center">March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center">2019</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Cost Basis</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross Unrealized Gains</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross Unrealized Losses</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Fair Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> U.S. Treasury securities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,657</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 9</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right">  —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,666</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,657</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,666</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Certain short-term debt securities with original maturities of less than 90 days are included in cash and cash equivalents on the condensed consolidated balance sheet and are not included in the table above. As of March 31, 2019, all investments have contractual maturities within one year. The Company had no investments as of December 31, 2018. </div>

<div> Recently Issued Accounting Pronouncements There have been no new accounting pronouncements or changes to accounting pronouncements during the three months ended March 31, 2019, as compared to the recent accounting pronouncements described in Note 2 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, which could be expected to materially impact the Company’s unaudited condensed consolidated financial statements. </div>

443000

-44809000

-8232000

-7697000

3000

8118000

274000

-8118000

199000

9000

44562000

247000

<div> 6. CONVERTIBLE PREFERRED STOCK Series A convertible preferred stock and Series B convertible preferred stock is collectively referred to as “Preferred Stock.” On October 23, 2018, upon the closing of the Company’s IPO, all outstanding shares of Preferred Stock converted into 11,789,775 shares of the Company’s common stock. As such, there were no outstanding shares of Preferred Stock as of March 31, 2019 and December 31, 2018. The rights and privileges of the preferred stockholders were as follows: Conversion: Each share of Preferred Stock was convertible, at the option of the holder, at any time, into shares of common stock on a one-for-1.90993 basis. The conversion ratio was determined by dividing the original issue price of $1.4933 by the conversion price of $0.78186. The Preferred Stock would automatically convert into shares of common stock at the closing a Qualified IPO (as defined in the Company’s amended and restated certificate of incorporation, as amended from time to time) or in a non-Qualified IPO, upon the approval of at least 60% of the preferred stockholders. Liquidation Preference: Prior to the IPO, in the event of any liquidation or “Deemed Liquidation Event,” defined below, the preferred stockholders would have been entitled to the greater of (i) the original issue price of the Preferred Stock plus any accrued dividends not yet paid plus any other dividends declared and unpaid or (ii) the amount payable had all classes of shares been converted to common stock. In the event of a Deemed Liquidation Event, accrued dividends would not exceed 40% of the original issue price. After payments of all preferential amounts are made to the preferred stockholders, any remaining assets would be distributed to the common stockholders on a pro rata basis. A Deemed Liquidation Event was defined as a merger, consolidation, reorganization or similar transaction; the sale transfer, exclusive license of all or substantially all of the Company’s assets/intellectual property; or the sale or transfer of shares to any person (or group of related or affiliated persons), directly or indirectly, representing a greater than 50% of the voting power of the voting securities of the Company. Dividends: Preferred stockholders were entitled to receive, when and if declared by the board of directors (the “Board”) out of any funds legally available, dividends at the rate of 8% of the original issue price per share. No dividends were declared or paid through October 23, 2018, the date on which all of the Preferred Stock was converted to common stock upon the closing of the Company’s IPO. Voting Rights: Preferred Stock and common stock voted together as one class on an as converted basis. </div>

-7697000

<div> 11. RELATED PARTIES From time to time, the Company is or has been party to consulting service agreements with each of its three founders. Under the terms of each agreement, the Company pays an annual fee of $68 for research and development consulting services. For the three months ended March 31, 2019 and 2018, the Company has made payments totaling $51 and $34, respectively, under these consulting service agreements. In addition, each founder receives $5 annually for their participation on the scientific advisory board (the “SAB”), beginning in 2018. Each founder has also received stock options for their services as either a member of the Board or member of the SAB. In March 2017, the Company subleased to an affiliate certain space in Tel Aviv, Israel, through June 2018. For the three months ended March 31, 2018, the Company recognized income of $13 in other income, net. </div>

5486000

1323000

<div> The Company excluded the following potential common stock equivalents from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect for the three months ended March 31, 2019 and 2018:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2019</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Preferred Stock </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,789,775</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Unvested restricted stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">724,383</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,260,892</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Options to purchase common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,429,562</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,521,184</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> </div>

<div> The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="44%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Quoted Prices in</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Significant Other</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Significant Other</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Active Markets</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Observable</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Observable</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">for Identical</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Inputs</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Inputs</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom" nowrap="nowrap"> Description </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2019</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Assets (Level 1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">(Level 2)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">(Level 3)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Sweep bank account </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,305</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,305</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right">—</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Money market funds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24,963</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24,963</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> U.S. Treasury securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44,666</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44,666</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total financial assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">71,934</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">71,934</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right">—</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Quoted Prices in</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Significant Other</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Significant Other</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Active Markets</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Observable</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Observable</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">for Identical</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Inputs</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Inputs</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom" nowrap="nowrap"> Description </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Assets (Level 1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">(Level 2)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">(Level 3)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Sweep bank account </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">831</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">831</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Money market funds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">79,212</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">79,212</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total financial assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">80,043</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">80,043</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Accrued expenses and other current liabilities at March 31, 2019 and December 31, 2018 consisted of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2019</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accrued compensation and benefits </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">281</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">709</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accrued professional services </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">579</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">585</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Lease liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,201</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">293</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">223</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total accrued expenses and other current liabilities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,354</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,517</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

276000

<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Significant Accounting Policies <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company’s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on April 1, 2019. Since the date of those financial statements, there have been no material changes to its significant accounting policies other than the Company’s adoption of ASC 842 (defined below) and the Company’s significant accounting policy over investments, both of which are discussed in this note. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Leases <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Effective January 1, 2019, the Company adopted ASC Topic 842, Leases (“ASC 842”), using the modified retrospective method and utilized the effective date as its date of initial application, with prior periods presented in accordance with the previous guidance under ASC 840, Leases (“ASC 840”). <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Most leases with a term greater than one year are recognized on the balance sheet as a right-of-use asset and a current and non-current lease liability, as applicable. The Company elected not to recognize on the balance sheet leases with terms of one year or less. The Company typically only includes an initial lease term in its assessment of a leasing arrangement. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew the lease. The Company remeasures and relocates the consideration in a contract when there is a modification of a lease that is not accounted for as a separate contract. A lease modification that results in a separate contract, including when the modification grants the lessee an additional right of use that is not included in the original lease, is accounted for in the same manner as a new lease. The Company monitors its material leases on a quarterly basis. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In accordance with ASC 842, components of a lease should be split into three categories: lease components (e.g., land, building, etc.), non-lease components (e.g., common area maintenance, consumables, etc.) and non-components(e.g., property taxes, insurance, etc.). The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Although separation of lease and non-lease components is required, certain practical expedients are available. Entities may elect the practical expedient not to separate lease and non-lease components. Rather, entities would account for each lease component and the related non-lease component together as a single component. For new and amended leases beginning in 2019 and after, the Company has elected to account for the lease and non-lease components for leases for classes of all underlying assets together and allocate all of the contract consideration to the lease component only. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Investments <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company determines the appropriate classification of its investments in debt securities at the time of purchase. All of the Company’s securities are classified as available-for-sale and are reported in short-term investments or long-term investments based on maturity dates and whether such assets are reasonably expected to be realized in cash or sold or consumed during the normal cycle of business. Available-for-sale investments are recorded at fair value, with unrealized gains or losses included in accumulated other comprehensive gain (loss) on the Company’s consolidated balance sheets, exclusive of other-than-temporary impairment losses, if any. Investments may be composed of corporate debt securities, commercial paper, U.S. government and agency securities and certificates of deposit. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Recently Adopted Accounting Pronouncements <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, “Leases (Topic 842),” which requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases on their balance sheet date. ASU No. 2016-02 is effective for fiscal years beginning after December 15, 2018. In July 2018, an amendment was made that allows companies the option of using the effective date of the new standard as the initial application date (at the beginning of the period in which the new standard is adopted, rather than at the beginning of the earliest comparative period). This update includes a short-term lease exception for leases with a term of 12 months or less, in which a lessee can make an accounting policy election not to recognize the associated lease assets and lease liabilities on its balance sheet. Additionally, in March 2019, the FASB issued ASU 2019-01, Leases (Topic 842): Codification Improvements (“ASU No. 2019-01”). ASU No. 2019-01 clarifies the transition guidance related to interim disclosures provided in the year of adoption. Lessees will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases, using classification criteria that are substantially similar to the previous guidance. For lessees, the recognition, measurement, and presentation of expenses and cash flows arising from a lease did not significantly change from previous U.S. GAAP. The modified retrospective method includes several optional practical expedients that entities may elect to apply, as well as transition guidance specific to nonstandard leasing transactions. The Company adopted Topic 842 on January 1, 2019 using a cumulative-effect adjustment on the effective date of the standard, for which comparative periods are presented in accordance with the previous guidance under ASC 840. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In adopting Topic 842, the Company elected to utilize the available package of practical expedients permitted under the transition guidance within the new standard, which does not require the reassessment of the following: i) whether existing or expired arrangements are or contain a lease, ii) the lease classification of existing or expired leases, and iii) whether previous initial direct costs would qualify for capitalization under the new lease standard. Additionally, the Company made an accounting policy election to keep leases with a term of 12 months or less off its balance sheet. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Adoption of this standard resulted in the recording of operating lease liabilities and a right-of-use asset of $210 and $210, respectively, on the Company’s condensed consolidated balance sheet on the effective date. The adoption of the standard did not have a material effect on the Company’s condensed consolidated statements of operations and comprehensive loss, condensed consolidated statements of cash flows or accumulated deficit. Refer to note 10 for right-of-use asset and liabilities recorded during the three months ended March 31, 2019. <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Recently Issued Accounting Pronouncements <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> There have been no new accounting pronouncements or changes to accounting pronouncements during the three months ended March 31, 2019, as compared to the recent accounting pronouncements described in Note 2 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, which could be expected to materially impact the Company’s unaudited condensed consolidated financial statements. </div>

<div> Basic loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding, without consideration to common stock equivalents:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2019</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Numerator: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Net loss </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(7,697</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,304</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Less: accruals of dividends of Preferred Stock </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,603</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Net loss attributable to common stockholders—basic and diluted </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(7,697</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(4,907</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Denominator: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Weighted-average common stock outstanding </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,313,129</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,787,342</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Net loss per share attributable to common stockholders—basic and diluted </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.34</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2.75</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Total stock-based compensation expense recorded as research and development and general and administrative expenses, respectively, for employees, directors and non-employees for the three ended March 31, 2019 and 2018 is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="81%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2019</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">155</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">48</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">121</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">40</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total stock-based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">276</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">88</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

LOGC

42000

22313129

274000 -7697000 3 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> 10. LEASES <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company has historically entered into lease arrangements for its facilities and certain equipment. As of March 31, 2019, the Company had three operating leases with required future minimum payments. In applying the transition guidance under ASC 842, the Company determined the classification of these leases to be operating leases and recorded a right-of-use asset and lease liabilities as of the effective date. The Company’s leases generally do not include termination or purchase options. From time to time, leases may include options to renew the lease after the expiration of the initial lease term. A renewal period is included in the lease term only when it reasonably certain that the Company will exercise such renewal options. As of March 31, 2019, no renewal options existed that the Company felt were reasonably certain of being exercised. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Operating Leases <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In December 2018, the Company entered into an operating lease for laboratory and office space in Cambridge, Massachusetts for a 14-month term, ending in March 2020. As required under the terms of the lease agreement as collateral for the facility lease, the Company had restricted cash of $146 in the form of a certificate deposit as of March 31, 2019 and December 31, 2018. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The following table contains a summary of the lease costs recognized under Topic 842 and other information pertaining to the Company’s operating leases for the three months ended March 31, 2019: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="77%"></td> <td valign="bottom" width="18%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom" nowrap="nowrap">Operating leases</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Three Months Ended March 31, 2019</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Lease cost </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Operating lease cost </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">274</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Variable lease cost </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">42</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Total lease cost </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">316</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other quarterly lease information </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Operating cash flows used for operating leases </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">199</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Operating lease liabilities arising from obtaining right-of-use assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,323</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom" nowrap="nowrap">Other operating lease information</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">As of March 31, 2019</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Operating lease liabilities—short term </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,201</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Operating lease liabilities—long term </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">58</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Weighted average remaining lease term </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.1 years</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Weighted average discount rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.04</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The variable lease costs for the quarter ended March 31, 2019 include common area maintenance and other operating charges. As the Company’s leases do not provide an implicit rate, the Company utilized its incremental borrowing rate based on what we would normally pay to borrow on a collateralized basis over a similar term for an amount equal to the lease payments at the commencement date in determining the present value of lease payments. As of March 31, 2019, the Company classified its short term and long term operating lease liabilities within accrued expenses and other current liabilities and other liabilities, respectively. <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Future minimum lease payments under the Company’s operating leases as of March 31, 2019 and December 31, 2018, were as follows: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom">Maturity of lease liabilities</td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center">As of</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center">As of</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom" nowrap="nowrap"> (in thousands) </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2019</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> 2019 </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,028</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">936</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> 2020 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">223</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">377</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Thereafter </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Total lease payments </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,251</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,313</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Less: imputed interest </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(54</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Total operating lease liabilities at March 31, 2019 </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,259</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Recently Adopted Accounting Pronouncements <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, “Leases (Topic 842),” which requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases on their balance sheet date. ASU No. 2016-02 is effective for fiscal years beginning after December 15, 2018. In July 2018, an amendment was made that allows companies the option of using the effective date of the new standard as the initial application date (at the beginning of the period in which the new standard is adopted, rather than at the beginning of the earliest comparative period). This update includes a short-term lease exception for leases with a term of 12 months or less, in which a lessee can make an accounting policy election not to recognize the associated lease assets and lease liabilities on its balance sheet. Additionally, in March 2019, the FASB issued ASU 2019-01, Leases (Topic 842): Codification Improvements (“ASU No. 2019-01”). ASU No. 2019-01 clarifies the transition guidance related to interim disclosures provided in the year of adoption. Lessees will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases, using classification criteria that are substantially similar to the previous guidance. For lessees, the recognition, measurement, and presentation of expenses and cash flows arising from a lease did not significantly change from previous U.S. GAAP. The modified retrospective method includes several optional practical expedients that entities may elect to apply, as well as transition guidance specific to nonstandard leasing transactions. The Company adopted Topic 842 on January 1, 2019 using a cumulative-effect adjustment on the effective date of the standard, for which comparative periods are presented in accordance with the previous guidance under ASC 840. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In adopting Topic 842, the Company elected to utilize the available package of practical expedients permitted under the transition guidance within the new standard, which does not require the reassessment of the following: i) whether existing or expired arrangements are or contain a lease, ii) the lease classification of existing or expired leases, and iii) whether previous initial direct costs would qualify for capitalization under the new lease standard. Additionally, the Company made an accounting policy election to keep leases with a term of 12 months or less off its balance sheet. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Adoption of this standard resulted in the recording of operating lease liabilities and a right-of-use asset of $210 and $210, respectively, on the Company’s condensed consolidated balance sheet on the effective date. The adoption of the standard did not have a material effect on the Company’s condensed consolidated statements of operations and comprehensive loss, condensed consolidated statements of cash flows or accumulated deficit. Refer to note 10 for right-of-use asset and liabilities recorded during the three months ended March 31, 2019. </div> 0.50 0.08

2429562000

724383000

P2Y2M12D

6.03

210000

66000

P8M12D

121000

155000

276000

79123

51000

68000

51000

68000

51000

68000

0.40 0.60 3

276000

3000

9000

160337

-7697000

0001664106 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001664106 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001664106 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001664106 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001664106 logc:SeriesAConvertiblePreferredStockMember 2019-01-01 2019-03-31 0001664106 logc:SeriesBConvertiblePreferredStockMember 2019-01-01 2019-03-31 0001664106 logc:ConsultingAgreementsMember 2019-01-01 2019-03-31 0001664106 srt:MinimumMemberus-gaap:IPOMember 2019-01-01 2019-03-31 0001664106 srt:MaximumMember 2019-01-01 2019-03-31 0001664106 logc:RelatedPartyOneMemberlogc:ConsultingAgreementsMember 2019-01-01 2019-03-31 0001664106 logc:RelatedPartyThreeMemberlogc:ConsultingAgreementsMember 2019-01-01 2019-03-31 0001664106 logc:RelatedPartyTwoMemberlogc:ConsultingAgreementsMember 2019-01-01 2019-03-31 0001664106 logc:TwoThousandFourteenAndEighteenPlanMember 2019-01-01 2019-03-31 0001664106 us-gaap:ResearchAndDevelopmentExpenseMemberlogc:TwoThousandFourteenAndEighteenPlanMember 2019-01-01 2019-03-31 0001664106 us-gaap:GeneralAndAdministrativeExpenseMemberlogc:TwoThousandFourteenAndEighteenPlanMember 2019-01-01 2019-03-31 0001664106 us-gaap:RestrictedStockMemberlogc:TwoThousandFourteenAndEighteenPlanMember 2019-01-01 2019-03-31 0001664106 us-gaap:EmployeeStockOptionMemberlogc:TwoThousandFourteenAndEighteenPlanMember 2019-01-01 2019-03-31 0001664106 us-gaap:EmployeeStockOptionMemberlogc:TwoThousandFourteenPlanMember 2019-01-01 2019-03-31 0001664106 us-gaap:RestrictedStockMember 2019-01-01 2019-03-31 0001664106 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001664106 2019-01-01 2019-03-31 0001664106 country:IL 2018-01-01 2018-03-31 0001664106 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001664106 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001664106 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0001664106 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001664106 logc:SeriesAConvertiblePreferredStockMember 2018-01-01 2018-03-31 0001664106 logc:SeriesBConvertiblePreferredStockMember 2018-01-01 2018-03-31 0001664106 logc:RelatedPartyOneMemberlogc:ConsultingAgreementsMember 2018-01-01 2018-03-31 0001664106 logc:RelatedPartyThreeMemberlogc:ConsultingAgreementsMember 2018-01-01 2018-03-31 0001664106 logc:RelatedPartyTwoMemberlogc:ConsultingAgreementsMember 2018-01-01 2018-03-31 0001664106 logc:TwoThousandFourteenAndEighteenPlanMember 2018-01-01 2018-03-31 0001664106 us-gaap:ResearchAndDevelopmentExpenseMemberlogc:TwoThousandFourteenAndEighteenPlanMember 2018-01-01 2018-03-31 0001664106 us-gaap:GeneralAndAdministrativeExpenseMemberlogc:TwoThousandFourteenAndEighteenPlanMember 2018-01-01 2018-03-31 0001664106 us-gaap:RestrictedStockMemberlogc:TwoThousandFourteenAndEighteenPlanMember 2018-01-01 2018-03-31 0001664106 us-gaap:EmployeeStockOptionMemberlogc:TwoThousandFourteenAndEighteenPlanMember 2018-01-01 2018-03-31 0001664106 us-gaap:EmployeeStockOptionMemberlogc:TwoThousandFourteenPlanMember 2018-01-01 2018-03-31 0001664106 us-gaap:RestrictedStockMember 2018-01-01 2018-03-31 0001664106 us-gaap:PreferredStockMember 2018-01-01 2018-03-31 0001664106 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-03-31 0001664106 2018-01-01 2018-03-31 0001664106 logc:ScientificAdvisoryBoardMemberlogc:RelatedPartyOneMemberlogc:ConsultingAgreementsMember 2018-01-01 2018-12-31 0001664106 logc:ScientificAdvisoryBoardMemberlogc:RelatedPartyThreeMemberlogc:ConsultingAgreementsMember 2018-01-01 2018-12-31 0001664106 logc:ScientificAdvisoryBoardMemberlogc:RelatedPartyTwoMemberlogc:ConsultingAgreementsMember 2018-01-01 2018-12-31 0001664106 logc:TwoThousandAndEighteenPlanMember 2018-01-01 2018-12-31 0001664106 country:MA 2018-12-01 2018-12-31 0001664106 country:IL 2017-03-01 2017-03-31 0001664106 us-gaap:IPOMember 2018-10-23 2018-10-23 0001664106 2018-10-23 2018-10-23 0001664106 us-gaap:IPOMember 2018-12-31 0001664106 country:MA 2018-12-31 0001664106 us-gaap:RetainedEarningsMember 2018-12-31 0001664106 us-gaap:CommonStockMember 2018-12-31 0001664106 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001664106 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001664106 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001664106 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001664106 logc:SweepBankAccountMemberus-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001664106 logc:SweepBankAccountMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001664106 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001664106 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001664106 2018-12-31 0001664106 us-gaap:RetainedEarningsMember 2017-12-31 0001664106 us-gaap:CommonStockMember 2017-12-31 0001664106 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001664106 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001664106 logc:SeriesAConvertiblePreferredStockMember 2017-12-31 0001664106 logc:SeriesBConvertiblePreferredStockMember 2017-12-31 0001664106 2017-12-31 0001664106 us-gaap:IPOMember 2019-03-31 0001664106 us-gaap:RetainedEarningsMember 2019-03-31 0001664106 us-gaap:CommonStockMember 2019-03-31 0001664106 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001664106 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001664106 logc:TwoThousandAndEighteenPlanMember 2019-03-31 0001664106 us-gaap:USTreasurySecuritiesMember 2019-03-31 0001664106 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2019-03-31 0001664106 us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0001664106 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2019-03-31 0001664106 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0001664106 logc:SweepBankAccountMemberus-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0001664106 logc:SweepBankAccountMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0001664106 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0001664106 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0001664106 us-gaap:RestrictedStockMemberlogc:TwoThousandFourteenAndEighteenPlanMember 2019-03-31 0001664106 us-gaap:EmployeeStockOptionMemberlogc:TwoThousandFourteenPlanMember 2019-03-31 0001664106 us-gaap:AccountingStandardsUpdate201602Member 2019-03-31 0001664106 2019-03-31 0001664106 us-gaap:IPOMember 2018-10-23 0001664106 logc:SeriesBConvertiblePreferredStockMember 2018-10-23 0001664106 2018-10-23 0001664106 us-gaap:RetainedEarningsMember 2018-03-31 0001664106 us-gaap:CommonStockMember 2018-03-31 0001664106 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001664106 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001664106 logc:SeriesAConvertiblePreferredStockMember 2018-03-31 0001664106 logc:SeriesBConvertiblePreferredStockMember 2018-03-31 0001664106 us-gaap:RestrictedStockMemberlogc:TwoThousandFourteenAndEighteenPlanMember 2018-03-31 0001664106 us-gaap:EmployeeStockOptionMemberlogc:TwoThousandFourteenPlanMember 2018-03-31 0001664106 2018-03-31 0001664106 2019-05-10 0001664106 logc:TwoThousandAndEighteenPlanMember 2018-10-31 shares iso4217:USD iso4217:USD shares pure logc:Founders EX-101.SCH 6 logc-20190331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) link:calculationLink link:presentationLink link:definitionLink 108 - Statement - Condensed Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - FAIR VALUE MEASUREMENTS link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - INVESTMENTS link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - CONVERTIBLE PREFERRED STOCK link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - STOCK-BASED COMPENSATION link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - INCOME TAXES link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - LOSS PER SHARE link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - LEASES link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - RELATED PARTIES link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - INVESTMENTS (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - LOSS PER SHARE (Tables) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - LEASES (Tables) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Investments - Summary of Investments (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Investments - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Convertible Preferred Stock - Convertible Preferred Stock - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Stock-Based Compensation - Compensation Related Costs Share based Payments - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Loss Per Share - Computation of Potentially Anti-Dilutive Securities (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Leases - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Leases - Summary of Lease Costs (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Leases - Summary of Future Minimum Lease Payments (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Related Parties - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 logc-20190331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 logc-20190331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 logc-20190331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Policies [Abstract] Accounting Policies [Abstract] Accounting Standards Update 2016-02 [Member] Accounting Standards Update 2016-02 [Member] Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accounts Payable, Current Accounts payable Accretion (Amortization) of Discounts and Premiums, Investments Net amortization of premiums and discounts on investments Accruals of dividends of preferred stock. Accruals of Dividends of Preferred Stock Less: accruals of dividends of Preferred Stock Accrued Expenses And Other Liabilities Current Accrued Expenses And Other Liabilities Current Total accrued expenses and other current liabilities Accrued Liabilities, Current Accrued expenses and other current liabilities Accrued Professional Fees, Current Accrued professional services Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income (loss) AOCI Attributable to Parent [Member] Accumulated Other Comprehensive (Loss) Income [Member] Additional Paid in Capital Additional paid-in capital Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock-based compensation expense Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Allocated Share-based Compensation Expense Stock- based compensation expense for options granted Total stock-based compensation expense Amendment Flag Amendment Flag Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Potential dilutive securities excluded from computation of diluted net loss per common share Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Assets TOTAL ASSETS Assets [Abstract] ASSETS Assets, Current Total current assets Assets, Current [Abstract] CURRENT ASSETS: Assets, Fair Value Disclosure Total financial assets Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Gross Unrealized Losses Debt Securities, Available-for-sale, Amortized Cost Cost Basis Debt Securities, Available-for-sale, Current Fair Value Investments Award Type [Axis] Award Type [Axis] Basis of Accounting, Policy [Policy Text Block] Significant Accounting Policies Business Description and Basis of Presentation [Text Block] NATURE OF BUSINESS AND BASIS OF PRESENTATION Capital Expenditures Incurred but Not yet Paid Property and equipment purchases in accounts payable and accrued expenses Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash at end of period Cash, cash equivalents and restricted cash at beginning of year Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract] RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH Class of Stock by Class [Table] Class of Stock by Class [Table] Class of Stock by Class [Table] Class of Stock Disclosures [Abstract] Class of Stock Disclosures [Abstract] Class of Stock [Domain] Class of Stock [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Common Stock Conversion Basis Ratio Common Stock Conversion Basis Ratio Common stock conversion ratio Common Stock [Member] Common Stock [Member] Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Value, Issued Common stock, par value of $0.0001 per share; 175,000,000 shares authorized as of March 31, 2019 and December 31, 2018, respectively; 22,348,730 and 22,188,393 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Consulting Agreements [Member] Consulting Agreements [Member] Consulting Agreements [Member] Conversion Price Per Share Conversion Price Per Share Conversion price per share Convertible Preferred Stock, Shares Issued upon Conversion Conversion of preferred stock shares into common stock shares Current Fiscal Year End Date Current Fiscal Year End Date Debt Securities, Available-for-sale [Table Text Block] Summary of Investments Denominator [Abstract] Denominator [Abstract] Denominator: Depreciation, Depletion and Amortization, Nonproduction Depreciation expense Dilutive Securities Included And Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Dilutive Securities Included And Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Dilutive Securities Included And Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] STOCK-BASED COMPENSATION Dividends Dividends declared Document and entity information. Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Information [Line Items] Document Information [Line Items] Document Information [Table] Document Information [Table] Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share [Abstract] Earnings Per Share [Abstract] Earnings Per Share, Basic and Diluted Net loss per share attributable to common stockholders - basic and diluted Net loss per share attributable to common stockholders-basic and diluted Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share [Text Block] LOSS PER SHARE Effect of Exchange Rate on Cash and Cash Equivalents Effect on foreign exchange rates on cash and cash equivalents Employee-related Liabilities, Current Accrued compensation and benefits Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Unrecognized compensation cost, recognition period Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Unrecognized compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Unrecognized compensation cost Employee Stock Option [Member] Options to Purchase Common Stock Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Entity Small Business Entity Small Business Equity [Abstract] Equity [Abstract] Equity Component [Domain] Equity Component [Domain] Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring Basis [Table] Fair Value Assets And Liabilities Measured On Recurring Basis [Table] Fair Value Assets And Liabilities Measured On Recurring Basis [Table] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] FAIR VALUE MEASUREMENTS Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Fair Value, Measurements, Recurring [Member] Fair Value, Measurements, Recurring [Member] Financial Instrument [Axis] Financial Instrument [Axis] General and Administrative Expense General and administrative General and Administrative Expense [Member] General and Administrative Expense [Member] ISRAEL Israel Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before income taxes Income Statement [Abstract] Income Statement [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] INCOME TAXES Income Taxes Paid, Net Cash paid for taxes Income Tax Expense (Benefit) Income tax provision Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued expenses and other current liabilities Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Other Operating Assets Other assets Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Interest Income (Expense), Nonoperating, Net Interest income, net Investment, Policy [Policy Text Block] Investments Investments Schedule [Abstract] Investments Schedule [Abstract] Investment [Text Block] INVESTMENTS IPO [Member] IPO [Member] Lease, Cost Total lease cost Lease, Cost [Table Text Block] Summary of Lease Costs Leases [Abstract] Leases [Abstract] Leases Disclosure [Text Block] Leases Disclosure [Text Block] LEASES Legal Entity [Axis] Legal Entity [Axis] Lessee, Leases [Policy Text Block] Leases Lessee, Operating Lease, Liability, Payments, Due Total lease payments Lessee, Operating Lease, Liability, Payments, Due after Year Five Thereafter Lessee, Operating Lease, Liability, Payments, Due Year Two 2020 Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 2019 Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: imputed interest Lessee, Operating Lease, Term of Contract Operating lease expiration period Liabilities Total liabilities Liabilities and Equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current Total current liabilities Liabilities, Current [Abstract] CURRENT LIABILITIES: MOROCCO Massachusetts Maximum [Member] Maximum [Member] Minimum [Member] Minimum [Member] Minimum voting power percentage upon liquidation. Minimum Voting Power Percentage Upon Liquidation Minimum voting power percentage upon liquidation Money Market Funds [Member] Money Market Funds [Member] Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Income (Loss) Attributable to Parent Net loss Net loss Net Income Loss Available To Common Stockholders Basic And Diluted Net Income Loss Available To Common Stockholders Basic And Diluted Net loss attributable to common stockholders-basic and diluted (Note 9) Net loss attributable to common stockholders - basic and diluted New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued Accounting Pronouncements Non-cash lease expense. Non Cash Lease Expense Non-cash lease expense Nonoperating Income (Expense) Total other income, net Number of Founders Number of Founders Number of founders Numerator [Abstract] Numerator [Abstract] Numerator: Operating Expenses Total operating expenses Operating Expenses [Abstract] OPERATING EXPENSES: Operating Income (Loss) LOSS FROM OPERATIONS Operating Lease, Cost Operating lease cost Operating Lease, Liability Operating lease liabilities Total operating lease liabilities at March 31, 2019 Operating Lease, Liability, Current Lease liabilities Operating lease liabilities-short term Operating Lease, Liability, Noncurrent Operating lease liabilities-long term Operating Lease Number Of Leases Operating Lease Number Of Leases Number of operating leases Operating Lease, Payments Operating cash flows used for operating leases Operating Lease, Right-of-Use Asset Operating lease right-of-use asset Operating Leases Expiration Month And Year Operating Leases Expiration Month And Year Operating lease expiration date Operating Lease, Weighted Average Discount Rate, Percent Weighted average discount rate Operating Lease, Weighted Average Remaining Lease Term Weighted average remaining lease term Organization And Nature Of Business [Line Items] Organization And Nature Of Business [Line Items] Organization And Nature Of Business [Line Items] Organization And Nature Of Business [Table] Organization And Nature Of Business [Table] Organization And Nature Of Business [Table] Organization And Nature Of Business Textual [Abstract] Organization And Nature Of Business Textual [Abstract] Organization And Nature Of Business Textual [Abstract] Other Assets, Noncurrent Other assets Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation adjustment Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other comprehensive income: Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax Unrealized gain on investments Other Liabilities Other liabilities Other Liabilities, Current Other Other Nonoperating Income (Expense) Other income, net Other Nonoperating Income (Expense) [Abstract] OTHER INCOME, NET: Payables and Accruals [Abstract] Payables and Accruals [Abstract] Payments to Acquire Investments Purchase of investments Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Preferred stock accrued dividend rate percentage. Preferred Stock Accrued Dividend Rate Percentage Preferred stock accrued dividend rate percentage Preferred stock accrued dividend rate percentage upon liquidation. Preferred Stock Accrued Dividend Rate Percentage Upon Liquidation Preferred stock accrued dividend rate percentage upon liquidation Preferred Stock [Member] Preferred Stock Preferred Stock, Shares Outstanding Convertible preferred stock outstanding Preferred Stock [Text Block] CONVERTIBLE PREFERRED STOCK Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Proceeds from Issuance of Common Stock Proceeds from issuance of common stock Proceeds From Issuance Of Common Stock Net Proceeds From Issuance Of Common Stock Net Proceeds after underwriting discounts and commissions and offering costs EX-101.PRE 10 logc-20190331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2019	May 10, 2019
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Trading Symbol	LOGC
Entity Registrant Name	LogicBio Therapeutics, Inc.
Entity Central Index Key	0001664106
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		22,494,299

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
CURRENT ASSETS:
Cash and cash equivalents	$ 27,870	$ 80,906
Short-term investments	44,666
Prepaid expenses and other current assets	1,763	1,268
Total current assets	74,299	82,174
Property and equipment, net	880	590
Restricted cash	146	146
Operating lease right-of-use asset	1,259
Other assets	57
TOTAL ASSETS	76,641	82,910
CURRENT LIABILITIES:
Accounts payable	1,413	1,168
Accrued expenses and other current liabilities	2,354	1,517
Total current liabilities	3,767	2,685
Other liabilities	58
Total liabilities	3,825	2,685
STOCKHOLDERS' EQUITY:
Common stock, par value of $0.0001 per share; 175,000,000 shares authorized as of March 31, 2019 and December 31, 2018, respectively; 22,348,730 and 22,188,393 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively	3	3
Additional paid-in capital	107,749	107,473
Accumulated other comprehensive income (loss)	3	(9)
Accumulated deficit	(34,939)	(27,242)
Total stockholders' equity	72,816	80,225
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 76,641	$ 82,910

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	175,000,000	175,000,000
Common stock, shares issued	22,348,730	22,188,393
Common stock, shares outstanding	22,348,730	22,188,393

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
OPERATING EXPENSES:
Research and development	$ 5,486	$ 1,455
General and administrative	2,632	918
Total operating expenses	8,118	2,373
LOSS FROM OPERATIONS	(8,118)	(2,373)
OTHER INCOME, NET:
Interest income, net	443	68
Other income, net		3
Total other income, net	443	71
Loss before income taxes	(7,675)	(2,302)
Income tax provision	(22)	(2)
Net loss	(7,697)	(2,304)
Net loss attributable to common stockholders-basic and diluted (Note 9)	$ (7,697)	$ (4,907)
Net loss per share attributable to common stockholders-basic and diluted	$ (0.34)	$ (2.75)
Weighted-average common stock outstanding-basic and diluted	22,313,129	1,787,342

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Net loss	$ (7,697)	$ (2,304)
Other comprehensive income:
Unrealized gain on investments	9
Foreign currency translation adjustment	3	7
Comprehensive loss	$ (7,685)	$ (2,297)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Series A Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive (Loss) Income [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2017	$ (8,599)	$ 4,359	$ 28,703	$ 1	$ 1,035	$ (14)	$ (9,621)
Beginning Balance, Shares at Dec. 31, 2017		2,976,190	19,541,465	1,606,360
Vesting of restricted stock	0	$ 0	$ 0	$ 0	0	0	0
Vesting of restricted stock, Shares				173,717
Foreign currency translation adjustment	7					7
Stock-based compensation expense	88				88
Net loss	(2,304)						(2,304)
Ending Balance at Mar. 31, 2018	(10,808)	$ 4,359	$ 28,703	$ 1	1,123	(7)	(11,925)
Ending Balance, Shares at Mar. 31, 2018		2,976,190	19,541,465	1,780,077
Beginning Balance at Dec. 31, 2018	80,225			$ 3	107,473	(9)	(27,242)
Beginning Balance, Shares at Dec. 31, 2018				22,188,393
Vesting of restricted stock	0	$ 0	$ 0	$ 0	0	0	0
Vesting of restricted stock, Shares				160,337
Unrealized gain on investments	9					9
Foreign currency translation adjustment	3					3
Stock-based compensation expense	276				276
Net loss	(7,697)						(7,697)
Ending Balance at Mar. 31, 2019	$ 72,816			$ 3	$ 107,749	$ 3	$ (34,939)
Ending Balance, Shares at Mar. 31, 2019				22,348,730

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 17 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (7,697)	$ (2,304)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	39	9
Net amortization of premiums and discounts on investments	(95)
Stock-based compensation expense	276	88
Non-cash lease expense	274
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(498)	50
Other assets	(57)	(1)
Accounts payable	201	(670)
Accrued expenses and other current liabilities	(675)	(326)
Net cash used in operating activities	(8,232)	(3,154)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of investments	(44,562)
Purchase of property and equipment	(247)	(3)
Net cash used in investing activities	(44,809)	(3)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net cash provided by financing activities	0	0
Effect on foreign exchange rates on cash and cash equivalents	5	7
NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	(53,036)	(3,150)
Cash, cash equivalents and restricted cash at beginning of year	81,052	24,575
Cash, cash equivalents and restricted cash at end of period	28,016	21,425
RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH
Cash and cash equivalents	27,870	21,425
Restricted cash	146
Cash, cash equivalents and restricted cash at end of period	28,016	21,425
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for taxes	31	102
Right-of-use assets obtained in exchange for operating lease obligation	1,323
Property and equipment purchases in accounts payable and accrued expenses	$ 81	$ 2

XML 18 R8.htm IDEA: XBRL DOCUMENT

NATURE OF BUSINESS AND BASIS OF PRESENTATION

3 Months Ended

Mar. 31, 2019

NATURE OF BUSINESS AND BASIS OF PRESENTATION

1. NATURE OF BUSINESS AND BASIS OF PRESENTATION

XML 19 R9.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2019

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Significant Accounting Policies

Leases

In accordance with ASC 842, components of a lease should be split into three categories: lease components (e.g., land, building, etc.), non-lease components (e.g., common area maintenance, consumables, etc.) and non-components(e.g., property taxes, insurance, etc.). The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.

Investments

Recently Adopted Accounting Pronouncements

Recently Issued Accounting Pronouncements

XML 20 R10.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENTS

3 Months Ended

Mar. 31, 2019

FAIR VALUE MEASUREMENTS

3. FAIR VALUE MEASUREMENTS


			Quoted Prices in		Significant Other		Significant Other
			Active Markets		Observable		Observable
			for Identical		Inputs		Inputs
Description	March 31, 2019		Assets (Level 1)		(Level 2)		(Level 3)
Assets
Sweep bank account	$	2,305	$	2,305	$	—	$	—
Money market funds		24,963		24,963		—		—
U.S. Treasury securities		44,666		44,666		—		—

Total financial assets	$	71,934	$	71,934	$	—	$	—


			Quoted Prices in		Significant Other		Significant Other
			Active Markets		Observable		Observable
			for Identical		Inputs		Inputs
Description	December 31, 2018		Assets (Level 1)		(Level 2)		(Level 3)
Assets
Sweep bank account	$	831	$	831	$	—	$	—
Money market funds		79,212		79,212		—		—

Total financial assets	$	80,043	$	80,043	$	—	$	—

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 21 R11.htm IDEA: XBRL DOCUMENT

INVESTMENTS

3 Months Ended

Mar. 31, 2019

INVESTMENTS

4. INVESTMENTS


	March 31,
	2019
	Cost Basis		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
U.S. Treasury securities	$	44,657	$	9	$	—	$	44,666

Total	$	44,657	$	9	$	—	$	44,666

XML 22 R12.htm IDEA: XBRL DOCUMENT

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

3 Months Ended

Mar. 31, 2019

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

5. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued expenses and other current liabilities at March 31, 2019 and December 31, 2018 consisted of the following:


	March 31,		December 31,
	2019		2018
Accrued compensation and benefits	$	281	$	709
Accrued professional services		579		585
Lease liabilities		1,201		—
Other		293		223

Total accrued expenses and other current liabilities	$	2,354	$	1,517

XML 23 R13.htm IDEA: XBRL DOCUMENT

CONVERTIBLE PREFERRED STOCK

3 Months Ended

Mar. 31, 2019

CONVERTIBLE PREFERRED STOCK

6. CONVERTIBLE PREFERRED STOCK

Series A convertible preferred stock and Series B convertible preferred stock is collectively referred to as “Preferred Stock.”

The rights and privileges of the preferred stockholders were as follows:

Voting Rights: Preferred Stock and common stock voted together as one class on an as converted basis.

XML 24 R14.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION

3 Months Ended

Mar. 31, 2019

STOCK-BASED COMPENSATION

7. STOCK-BASED COMPENSATION

Equity Incentive Plans

In December 2014, the Company adopted the LogicBio Therapeutics, Inc. 2014 Equity Incentive Plan, as amended (the “2014 Plan”), for the issuance of stock options and other stock-based awards.


	Three Months Ended March 31,
	2019		2018
Research and development	$	155	$	48
General and administrative		121		40

Total stock-based compensation expense	$	276	$	88

XML 25 R15.htm IDEA: XBRL DOCUMENT

INCOME TAXES

3 Months Ended

Mar. 31, 2019

INCOME TAXES

8. INCOME TAXES

XML 26 R16.htm IDEA: XBRL DOCUMENT

LOSS PER SHARE

3 Months Ended

Mar. 31, 2019

LOSS PER SHARE

9. LOSS PER SHARE

Basic loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding, without consideration to common stock equivalents:


	Three Months Ended March 31,
	2019			2018
Numerator:
Net loss	$	(7,697	)	$	(2,304	)
Less: accruals of dividends of Preferred Stock		—			(2,603	)

Net loss attributable to common stockholders—basic and diluted	$	(7,697	)	$	(4,907	)

Denominator:
Weighted-average common stock outstanding		22,313,129			1,787,342

Net loss per share attributable to common stockholders—basic and diluted	$	(0.34	)	$	(2.75	)


	March 31,		March 31,
	2019		2018
Preferred Stock		—		11,789,775
Unvested restricted stock		724,383		1,260,892
Options to purchase common stock		2,429,562		1,521,184

XML 27 R17.htm IDEA: XBRL DOCUMENT

LEASES

3 Months Ended

Mar. 31, 2019

LEASES

10. LEASES

Operating Leases

The following table contains a summary of the lease costs recognized under Topic 842 and other information pertaining to the Company’s operating leases for the three months ended March 31, 2019:


Operating leases	Three Months Ended March 31, 2019
Lease cost
Operating lease cost	$	274
Variable lease cost		42

Total lease cost	$	316


Other quarterly lease information
Operating cash flows used for operating leases	$	199
Operating lease liabilities arising from obtaining right-of-use assets	$	1,323

Other operating lease information	As of March 31, 2019
Operating lease liabilities—short term	$	1,201
Operating lease liabilities—long term	$	58
Weighted average remaining lease term		1.1 years
Weighted average discount rate		7.04	%

Future minimum lease payments under the Company’s operating leases as of March 31, 2019 and December 31, 2018, were as follows:


Maturity of lease liabilities	As of		As of
(in thousands)	December 31, 2018		March 31, 2019
2019	$	1,028	$	936
2020		223		377
Thereafter		—		—

Total lease payments	$	1,251	$	1,313
Less: imputed interest				(54	)

Total operating lease liabilities at March 31, 2019			$	1,259

XML 28 R18.htm IDEA: XBRL DOCUMENT

RELATED PARTIES

3 Months Ended

Mar. 31, 2019

RELATED PARTIES

11. RELATED PARTIES

XML 29 R19.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Mar. 31, 2019
Significant Accounting Policies	Significant Accounting Policies The Company’s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on April 1, 2019. Since the date of those financial statements, there have been no material changes to its significant accounting policies other than the Company’s adoption of ASC 842 (defined below) and the Company’s significant accounting policy over investments, both of which are discussed in this note.
Leases	Leases Effective January 1, 2019, the Company adopted ASC Topic 842, Leases (“ASC 842”), using the modified retrospective method and utilized the effective date as its date of initial application, with prior periods presented in accordance with the previous guidance under ASC 840, Leases (“ASC 840”). At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Most leases with a term greater than one year are recognized on the balance sheet as a right-of-use asset and a current and non-current lease liability, as applicable. The Company elected not to recognize on the balance sheet leases with terms of one year or less. The Company typically only includes an initial lease term in its assessment of a leasing arrangement. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew the lease. The Company remeasures and relocates the consideration in a contract when there is a modification of a lease that is not accounted for as a separate contract. A lease modification that results in a separate contract, including when the modification grants the lessee an additional right of use that is not included in the original lease, is accounted for in the same manner as a new lease. The Company monitors its material leases on a quarterly basis. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates. In accordance with ASC 842, components of a lease should be split into three categories: lease components (e.g., land, building, etc.), non-lease components (e.g., common area maintenance, consumables, etc.) and non-components(e.g., property taxes, insurance, etc.). The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Although separation of lease and non-lease components is required, certain practical expedients are available. Entities may elect the practical expedient not to separate lease and non-lease components. Rather, entities would account for each lease component and the related non-lease component together as a single component. For new and amended leases beginning in 2019 and after, the Company has elected to account for the lease and non-lease components for leases for classes of all underlying assets together and allocate all of the contract consideration to the lease component only.
Investments	Investments The Company determines the appropriate classification of its investments in debt securities at the time of purchase. All of the Company’s securities are classified as available-for-sale and are reported in short-term investments or long-term investments based on maturity dates and whether such assets are reasonably expected to be realized in cash or sold or consumed during the normal cycle of business. Available-for-sale investments are recorded at fair value, with unrealized gains or losses included in accumulated other comprehensive gain (loss) on the Company’s consolidated balance sheets, exclusive of other-than-temporary impairment losses, if any. Investments may be composed of corporate debt securities, commercial paper, U.S. government and agency securities and certificates of deposit.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, “Leases (Topic 842),” which requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases on their balance sheet date. ASU No. 2016-02 is effective for fiscal years beginning after December 15, 2018. In July 2018, an amendment was made that allows companies the option of using the effective date of the new standard as the initial application date (at the beginning of the period in which the new standard is adopted, rather than at the beginning of the earliest comparative period). This update includes a short-term lease exception for leases with a term of 12 months or less, in which a lessee can make an accounting policy election not to recognize the associated lease assets and lease liabilities on its balance sheet. Additionally, in March 2019, the FASB issued ASU 2019-01, Leases (Topic 842): Codification Improvements (“ASU No. 2019-01”). ASU No. 2019-01 clarifies the transition guidance related to interim disclosures provided in the year of adoption. Lessees will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases, using classification criteria that are substantially similar to the previous guidance. For lessees, the recognition, measurement, and presentation of expenses and cash flows arising from a lease did not significantly change from previous U.S. GAAP. The modified retrospective method includes several optional practical expedients that entities may elect to apply, as well as transition guidance specific to nonstandard leasing transactions. The Company adopted Topic 842 on January 1, 2019 using a cumulative-effect adjustment on the effective date of the standard, for which comparative periods are presented in accordance with the previous guidance under ASC 840. In adopting Topic 842, the Company elected to utilize the available package of practical expedients permitted under the transition guidance within the new standard, which does not require the reassessment of the following: i) whether existing or expired arrangements are or contain a lease, ii) the lease classification of existing or expired leases, and iii) whether previous initial direct costs would qualify for capitalization under the new lease standard. Additionally, the Company made an accounting policy election to keep leases with a term of 12 months or less off its balance sheet. Adoption of this standard resulted in the recording of operating lease liabilities and a right-of-use asset of $210 and $210, respectively, on the Company’s condensed consolidated balance sheet on the effective date. The adoption of the standard did not have a material effect on the Company’s condensed consolidated statements of operations and comprehensive loss, condensed consolidated statements of cash flows or accumulated deficit. Refer to note 10 for right-of-use asset and liabilities recorded during the three months ended March 31, 2019.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements There have been no new accounting pronouncements or changes to accounting pronouncements during the three months ended March 31, 2019, as compared to the recent accounting pronouncements described in Note 2 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, which could be expected to materially impact the Company’s unaudited condensed consolidated financial statements.

- Definition

Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.

+ References + Details

XML 30 R20.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENTS (Tables)

3 Months Ended

Mar. 31, 2019

Financial Assets and Liabilities Measured at Fair Value on Recurring Basis


			Quoted Prices in		Significant Other		Significant Other
			Active Markets		Observable		Observable
			for Identical		Inputs		Inputs
Description	March 31, 2019		Assets (Level 1)		(Level 2)		(Level 3)
Assets
Sweep bank account	$	2,305	$	2,305	$	—	$	—
Money market funds		24,963		24,963		—		—
U.S. Treasury securities		44,666		44,666		—		—

Total financial assets	$	71,934	$	71,934	$	—	$	—


			Quoted Prices in		Significant Other		Significant Other
			Active Markets		Observable		Observable
			for Identical		Inputs		Inputs
Description	December 31, 2018		Assets (Level 1)		(Level 2)		(Level 3)
Assets
Sweep bank account	$	831	$	831	$	—	$	—
Money market funds		79,212		79,212		—		—

Total financial assets	$	80,043	$	80,043	$	—	$	—

XML 31 R21.htm IDEA: XBRL DOCUMENT

INVESTMENTS (Tables)

3 Months Ended

Mar. 31, 2019

Summary of Investments


	March 31,
	2019
	Cost Basis		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
U.S. Treasury securities	$	44,657	$	9	$	—	$	44,666

Total	$	44,657	$	9	$	—	$	44,666

XML 32 R22.htm IDEA: XBRL DOCUMENT

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)

3 Months Ended

Mar. 31, 2019

Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities at March 31, 2019 and December 31, 2018 consisted of the following:


	March 31,		December 31,
	2019		2018
Accrued compensation and benefits	$	281	$	709
Accrued professional services		579		585
Lease liabilities		1,201		—
Other		293		223

Total accrued expenses and other current liabilities	$	2,354	$	1,517

XML 33 R23.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Tables)

3 Months Ended

Mar. 31, 2019

Schedule of Stock-Based Compensation Expense


	Three Months Ended March 31,
	2019		2018
Research and development	$	155	$	48
General and administrative		121		40

Total stock-based compensation expense	$	276	$	88

XML 34 R24.htm IDEA: XBRL DOCUMENT

LOSS PER SHARE (Tables)

3 Months Ended

Mar. 31, 2019

Computation of Basic and Diluted Net Loss Per Share

Basic loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding, without consideration to common stock equivalents:


	Three Months Ended March 31,
	2019			2018
Numerator:
Net loss	$	(7,697	)	$	(2,304	)
Less: accruals of dividends of Preferred Stock		—			(2,603	)

Net loss attributable to common stockholders—basic and diluted	$	(7,697	)	$	(4,907	)

Denominator:
Weighted-average common stock outstanding		22,313,129			1,787,342

Net loss per share attributable to common stockholders—basic and diluted	$	(0.34	)	$	(2.75	)

Computation of Potentially Anti-Dilutive Securities


	March 31,		March 31,
	2019		2018
Preferred Stock		—		11,789,775
Unvested restricted stock		724,383		1,260,892
Options to purchase common stock		2,429,562		1,521,184

XML 35 R25.htm IDEA: XBRL DOCUMENT

LEASES (Tables)

3 Months Ended

Mar. 31, 2019

Summary of Lease Costs

The following table contains a summary of the lease costs recognized under Topic 842 and other information pertaining to the Company’s operating leases for the three months ended March 31, 2019:


Operating leases	Three Months Ended March 31, 2019
Lease cost
Operating lease cost	$	274
Variable lease cost		42

Total lease cost	$	316


Other quarterly lease information
Operating cash flows used for operating leases	$	199
Operating lease liabilities arising from obtaining right-of-use assets	$	1,323

Other operating lease information	As of March 31, 2019
Operating lease liabilities—short term	$	1,201
Operating lease liabilities—long term	$	58
Weighted average remaining lease term		1.1 years
Weighted average discount rate		7.04	%

Schedule of Future Minimum Rental Payments for Operating Leases

Future minimum lease payments under the Company’s operating leases as of March 31, 2019 and December 31, 2018, were as follows:


Maturity of lease liabilities	As of		As of
(in thousands)	December 31, 2018		March 31, 2019
2019	$	1,028	$	936
2020		223		377
Thereafter		—		—

Total lease payments	$	1,251	$	1,313
Less: imputed interest				(54	)

Total operating lease liabilities at March 31, 2019			$	1,259

XML 36 R26.htm IDEA: XBRL DOCUMENT

Nature of Business and Basis of Presentation - Additional Information (Detail) $ / shares in Units, $ in Thousands	Oct. 23, 2018 USD ($) $ / shares shares
Organization And Nature Of Business [Line Items]
Number of common shares sold	1,050,000
Conversion of preferred stock shares into common stock shares	11,789,775
Series B Convertible Preferred Stock [Member]
Organization And Nature Of Business [Line Items]
Convertible preferred stock outstanding	0
IPO [Member]
Organization And Nature Of Business [Line Items]
Number of common shares sold	8,050,000
Stock issued, price per share \| $ / shares	$ 10.00
Proceeds from issuance of common stock \| $	$ 80,500
Proceeds after underwriting discounts and commissions and offering costs \| $	$ 72,300
Conversion of preferred stock shares into common stock shares	11,789,775

XML 37 R27.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Additional Information (Detail) $ in Thousands	Mar. 31, 2019 USD ($)
Significant Accounting Policies [Line Items]
Operating lease liabilities	$ 1,259
Operating lease right-of-use asset	1,259
Accounting Standards Update 2016-02 [Member]
Significant Accounting Policies [Line Items]
Operating lease liabilities	210
Operating lease right-of-use asset	$ 210

XML 38 R28.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Total financial assets	$ 71,934	$ 80,043
U.S. Treasury Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Total financial assets	44,666
Sweep Bank Account [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Total financial assets	2,305	831
Money Market Funds [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Total financial assets	24,963	79,212
Fair Value, Inputs, Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Total financial assets	71,934	80,043
Fair Value, Inputs, Level 1 [Member] \| U.S. Treasury Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Total financial assets	44,666
Fair Value, Inputs, Level 1 [Member] \| Sweep Bank Account [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Total financial assets	2,305	831
Fair Value, Inputs, Level 1 [Member] \| Money Market Funds [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Total financial assets	$ 24,963	$ 79,212

XML 39 R29.htm IDEA: XBRL DOCUMENT

Investments - Summary of Investments (Detail) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Schedule of Investments [Line Items]
Cost Basis	$ 44,657
Gross Unrealized Gains	9
Gross Unrealized Losses	0
Fair Value	44,666	$ 0
U.S. Treasury Securities [Member]
Schedule of Investments [Line Items]
Cost Basis	44,657
Gross Unrealized Gains	9
Gross Unrealized Losses	0
Fair Value	$ 44,666

XML 40 R30.htm IDEA: XBRL DOCUMENT

Investments - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Investments	$ 44,666	$ 0

XML 41 R31.htm IDEA: XBRL DOCUMENT

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Accrued compensation and benefits	$ 281	$ 709
Accrued professional services	579	585
Lease liabilities	1,201
Other	293	223
Total accrued expenses and other current liabilities	$ 2,354	$ 1,517

XML 42 R32.htm IDEA: XBRL DOCUMENT

Convertible Preferred Stock - Convertible Preferred Stock - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended
	Oct. 23, 2018	Mar. 31, 2019	Dec. 31, 2018
Class of Stock [Line Items]
Conversion of preferred stock shares into common stock shares	11,789,775
Common stock conversion ratio		52.35%
Shares issued price per share		$ 1.4933
Conversion price per share		$ 0.78186
Minimum voting power percentage upon liquidation		50.00%
Preferred stock accrued dividend rate percentage		8.00%
Dividends declared	$ 0
Maximum [Member]
Class of Stock [Line Items]
Preferred stock accrued dividend rate percentage upon liquidation		40.00%
IPO [Member]
Class of Stock [Line Items]
Conversion of preferred stock shares into common stock shares	11,789,775
Convertible preferred stock shares outstanding		0	0
IPO [Member] \| Minimum [Member]
Class of Stock [Line Items]
Stockholders approval percentage		60.00%

XML 43 R33.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Compensation Related Costs Share based Payments - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Oct. 31, 2018
2018 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized				1,183,214
Percentage of shares issued on common stock outstanding			4.00%
Number of shares available for future grant	1,286,336
Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	79,123	120,121
Stock- based compensation expense for options granted	$ 276	$ 88
Plans \| Options to Purchase Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock- based compensation expense for options granted	210	31
Plans \| Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock- based compensation expense for options granted	$ 66	$ 57
Unrecognized compensation cost, recognition period	8 months 12 days	1 year 7 months 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	0	0
Stock options outstanding, unvested	724,383	1,260,892
Unrecognized compensation cost	$ 463	$ 344
2014 Plan \| Options to Purchase Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair values of options granted	$ 6.03	$ 0.46
Unrecognized compensation cost, recognition period	2 years 2 months 12 days	2 years 3 months 18 days
Unrecognized compensation cost	$ 5,003	$ 403
Stock options outstanding	2,429,562	1,521,184

XML 44 R34.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Detail) - Plans - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 276	$ 88
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	155	48
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 121	$ 40

XML 45 R35.htm IDEA: XBRL DOCUMENT

Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Numerator:
Net loss	$ (7,697)	$ (2,304)
Less: accruals of dividends of Preferred Stock		(2,603)
Net loss attributable to common stockholders - basic and diluted	$ (7,697)	$ (4,907)
Denominator:
Weighted - average common stock outstanding	22,313,129	1,787,342
Net loss per share attributable to common stockholders - basic and diluted	$ (0.34)	$ (2.75)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 46 R36.htm IDEA: XBRL DOCUMENT

Loss Per Share - Computation of Potentially Anti-Dilutive Securities (Detail) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Preferred Stock
Dilutive Securities Included And Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential dilutive securities excluded from computation of diluted net loss per common share		11,789,775
Restricted Stock
Dilutive Securities Included And Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential dilutive securities excluded from computation of diluted net loss per common share	724,383	1,260,892
Options to Purchase Common Stock
Dilutive Securities Included And Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential dilutive securities excluded from computation of diluted net loss per common share	2,429,562	1,521,184

XML 47 R37.htm IDEA: XBRL DOCUMENT

Leases - Additional Information (Detail) $ in Thousands	1 Months Ended	3 Months Ended
Leases - Additional Information (Detail) $ in Thousands	Dec. 31, 2018 USD ($)	Mar. 31, 2019 USD ($)
Number of operating leases		3
Restricted cash	$ 146	$ 146
Massachusetts
Operating lease expiration date	2020-03
Operating lease expiration period	14 months

XML 48 R38.htm IDEA: XBRL DOCUMENT

Leases - Summary of Lease Costs (Detail) $ in Thousands	3 Months Ended
Leases - Summary of Lease Costs (Detail) $ in Thousands	Mar. 31, 2019 USD ($)
Operating lease cost	$ 274
Variable lease cost	42
Total lease cost	316
Operating cash flows used for operating leases	199
Operating lease liabilities arising from obtaining right-of-use assets	1,323
Operating lease liabilities-short term	1,201
Operating lease liabilities-long term	$ 58
Weighted average remaining lease term	1 year 1 month 6 days
Weighted average discount rate	7.04%

XML 49 R39.htm IDEA: XBRL DOCUMENT

Leases - Summary of Future Minimum Lease Payments (Detail) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
2019	$ 936	$ 1,028
2020	377	223
Thereafter	0	0
Total lease payments	1,313	$ 1,251
Less: imputed interest	(54)
Total operating lease liabilities at March 31, 2019	$ 1,259

XML 50 R40.htm IDEA: XBRL DOCUMENT

Related Parties - Additional Information (Detail) $ in Thousands	1 Months Ended	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2019 USD ($) Founders	Mar. 31, 2018 USD ($)	Dec. 31, 2018 USD ($)
Israel
Schedule of Other Related Party Transactions [Line Items]
Subleases expiration month	2018-06
Sublease income			$ 13
Consulting Agreements [Member]
Schedule of Other Related Party Transactions [Line Items]
Number of founders \| Founders		3
Consulting Agreements [Member] \| Founder One [Member]
Schedule of Other Related Party Transactions [Line Items]
Consulting agreement annual fee		$ 68
Consulting fee		51	34
Consulting Agreements [Member] \| Founder One [Member] \| Scientific Advisory Board [Member]
Schedule of Other Related Party Transactions [Line Items]
Consulting fee				$ 5
Consulting Agreements [Member] \| Founder Two [Member]
Schedule of Other Related Party Transactions [Line Items]
Consulting agreement annual fee		68
Consulting fee		51	34
Consulting Agreements [Member] \| Founder Two [Member] \| Scientific Advisory Board [Member]
Schedule of Other Related Party Transactions [Line Items]
Consulting fee				5
Consulting Agreements [Member] \| Founder Three [Member]
Schedule of Other Related Party Transactions [Line Items]
Consulting agreement annual fee		68
Consulting fee		$ 51	$ 34
Consulting Agreements [Member] \| Founder Three [Member] \| Scientific Advisory Board [Member]
Schedule of Other Related Party Transactions [Line Items]
Consulting fee				$ 5

EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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Ʃ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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 53 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 54 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.1 html 102 164 1 false 32 0 false 5 false false R1.htm 101 - Document - Document and Entity Information Sheet http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Condensed Consolidated Balance Sheets Sheet http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 105 - Statement - Condensed Consolidated Statements of Operations Sheet http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncomeAlternative Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 106 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://imetrix.edgar-online.com/taxonomy/role/StatementOfOtherComprehensiveIncome Condensed Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 107 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) Sheet http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) Statements 6 false false R7.htm 108 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 109 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock NATURE OF BUSINESS AND BASIS OF PRESENTATION Notes 8 false false R9.htm 110 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 111 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock FAIR VALUE MEASUREMENTS Notes 10 false false R11.htm 112 - Disclosure - INVESTMENTS Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInvestmentTextBlock INVESTMENTS Notes 11 false false R12.htm 113 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Notes 12 false false R13.htm 114 - Disclosure - CONVERTIBLE PREFERRED STOCK Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPreferredStockTextBlock CONVERTIBLE PREFERRED STOCK Notes 13 false false R14.htm 115 - Disclosure - STOCK-BASED COMPENSATION Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock STOCK-BASED COMPENSATION Notes 14 false false R15.htm 116 - Disclosure - INCOME TAXES Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock INCOME TAXES Notes 15 false false R16.htm 117 - Disclosure - LOSS PER SHARE Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock LOSS PER SHARE Notes 16 false false R17.htm 118 - Disclosure - LEASES Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsLeasesDisclosureTextBlock LEASES Notes 17 false false R18.htm 119 - Disclosure - RELATED PARTIES Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock RELATED PARTIES Notes 18 false false R19.htm 120 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 19 false false R20.htm 121 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables FAIR VALUE MEASUREMENTS (Tables) Tables http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock 20 false false R21.htm 122 - Disclosure - INVESTMENTS (Tables) Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInvestmentTextBlockTables INVESTMENTS (Tables) Tables http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInvestmentTextBlock 21 false false R22.htm 123 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlockTables ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) Tables http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock 22 false false R23.htm 124 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables STOCK-BASED COMPENSATION (Tables) Tables http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock 23 false false R24.htm 125 - Disclosure - LOSS PER SHARE (Tables) Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables LOSS PER SHARE (Tables) Tables http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock 24 false false R25.htm 126 - Disclosure - LEASES (Tables) Sheet http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsLeasesDisclosureTextBlockTables LEASES (Tables) Tables http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsLeasesDisclosureTextBlock 25 false false R26.htm 127 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformation Nature of Business and Basis of Presentation - Additional Information (Detail) Details 26 false false R27.htm 128 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation Summary of Significant Accounting Policies - Additional Information (Detail) Details 27 false false R28.htm 129 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) Details 28 false false R29.htm 130 - Disclosure - Investments - Summary of Investments (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureInvestmentsSummaryOfInvestments Investments - Summary of Investments (Detail) Details 29 false false R30.htm 131 - Disclosure - Investments - Additional Information (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureInvestmentsAdditionalInformation Investments - Additional Information (Detail) Details 30 false false R31.htm 132 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilities Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) Details 31 false false R32.htm 133 - Disclosure - Convertible Preferred Stock - Convertible Preferred Stock - Additional Information (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureConvertiblePreferredStockConvertiblePreferredStockAdditionalInformation Convertible Preferred Stock - Convertible Preferred Stock - Additional Information (Detail) Details 32 false false R33.htm 134 - Disclosure - Stock-Based Compensation - Compensation Related Costs Share based Payments - Additional Information (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationCompensationRelatedCostsShareBasedPaymentsAdditionalInformation Stock-Based Compensation - Compensation Related Costs Share based Payments - Additional Information (Detail) Details 33 false false R34.htm 135 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpense Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Detail) Details 34 false false R35.htm 136 - Disclosure - Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureLossPerShareComputationOfBasicAndDilutedNetLossPerShare Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Detail) Details 35 false false R36.htm 137 - Disclosure - Loss Per Share - Computation of Potentially Anti-Dilutive Securities (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureLossPerShareComputationOfPotentiallyAntiDilutiveSecurities Loss Per Share - Computation of Potentially Anti-Dilutive Securities (Detail) Details 36 false false R37.htm 138 - Disclosure - Leases - Additional Information (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureLeasesAdditionalInformation Leases - Additional Information (Detail) Details 37 false false R38.htm 139 - Disclosure - Leases - Summary of Lease Costs (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureLeasesSummaryOfLeaseCosts Leases - Summary of Lease Costs (Detail) Details 38 false false R39.htm 140 - Disclosure - Leases - Summary of Future Minimum Lease Payments (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePayments Leases - Summary of Future Minimum Lease Payments (Detail) Details 39 false false R40.htm 141 - Disclosure - Related Parties - Additional Information (Detail) Sheet http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartiesAdditionalInformation Related Parties - Additional Information (Detail) Details 40 false false All Reports Book All Reports logc-20190331.xml logc-20190331.xsd logc-20190331_cal.xml logc-20190331_def.xml logc-20190331_lab.xml logc-20190331_pre.xml http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/invest/2013-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 true true ZIP 56 0001193125-19-146603-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-19-146603-xbrl.zip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